var title_f6_15_6384="Asbestosis CT";
var content_f6_15_6384=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan in asbestosis shows bibasilar opacities which are difficult to differentiate from gravitational changes without a prone scan. There are several small cystic, honeycomb-like changes at the left lung base as well as a pleural plaque in the right anterior hemithorax, findings which make the diagnosis of asbestosis likely.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6384=[""].join("\n");
var outline_f6_15_6384=null;
var title_f6_15_6385="Pulm bronchogen cyst CT I";
var content_f6_15_6385=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant intrapulmonary bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan shows a liquid-filled cyst in right lower lobe, compressing the adjacent lung.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6385=[""].join("\n");
var outline_f6_15_6385=null;
var title_f6_15_6386="Ovarian cancer screening";
var content_f6_15_6386=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Ovarian cancer screening (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/15/6386/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6386/contributors\" id=\"au1127\">",
"       Karen J Carlson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/15/6386/contributors\">",
"       Section Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6386/contributors\" id=\"se4183\">",
"       Suzanne W Fletcher, MD",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6386/contributors\" id=\"se7382\">",
"       Barbara Goff, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?6/15/6386/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6386/contributors\" id=\"de162\">",
"       H Nancy Sokol, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?6/15/6386?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Ovarian cancer is one of the deadliest cancers in women, in part because it is often found at late stage. There is a great deal of interest in finding a test or combination of tests that could detect ovarian cancer at an early, treatable stage. However, studies have not yet shown that screening tests decrease the risk of dying of ovarian cancer. Until more studies are completed:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Women with no family history of ovarian cancer are advised to",
"       <strong>",
"        not",
"       </strong>",
"       have ovarian cancer screening unless enrolled in a clinical trial (",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Women with a \"high-risk\" family history of ovarian cancer are at increased risk of ovarian cancer. Women with a particularly high risk may benefit from ovarian cancer screening. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'High risk family history'",
"       </a>",
"       below.)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     This article will review the risks and benefits of screening for ovarian cancer. Diagnosis, staging, and treatment of ovarian cancer are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"      \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      \"Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     More detailed information about ovarian cancer screening is available by subscription. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"      \"Screening for ovarian cancer\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      AM I AT RISK FOR OVARIAN CANCER?",
"     </span>",
"    </p>",
"    <p>",
"     Factors that increase your risk of ovarian cancer include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Older age",
"      </li>",
"      <li>",
"       Having one or more relatives with ovarian cancer",
"      </li>",
"      <li>",
"       Having abnormalities in a gene, called BRCA1 or BRCA2",
"      </li>",
"      <li>",
"       Having genes that are linked to hereditary nonpolyposis colorectal cancer (also called Lynch syndrome)",
"      </li>",
"      <li>",
"       Never being pregnant",
"      </li>",
"      <li>",
"       Being overweight",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some factors can reduce your risk of developing ovarian cancer, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Using hormonal methods of birth control (pills, patch, vaginal ring, injection)",
"      </li>",
"      <li>",
"       Being pregnant, breastfeeding",
"      </li>",
"      <li>",
"       Having your tubes tied to prevent pregnancy",
"      </li>",
"      <li>",
"       Having your uterus or ovaries removed",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      RISKS AND BENEFITS OF SCREENING",
"     </span>",
"    </p>",
"    <p>",
"     A screening test is one that can find a disease, such as cancer, in the early stages when there are no symptoms and when the cancer is most likely to respond to treatment. An example of a common screening test is the Pap smear, which is used to detect cervical precancers and cancers.",
"    </p>",
"    <p>",
"     A screening test must find most people with the condition and not mistakenly find people who do not have the condition. A test that is positive when no disease is present is termed a \"false positive\" test. It is especially important to avoid having false positive tests for ovarian cancer, since a positive screening test usually requires surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Benefits",
"     </span>",
"     &nbsp;&mdash;&nbsp;The potential benefit of ovarian cancer screening is the chance to find the cancer at a curable stage, reducing the risk of dying.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Risks",
"     </span>",
"     &nbsp;&mdash;&nbsp;The potential risk of ovarian cancer screening is a falsely positive screening test. This might lead to unnecessary surgery for many healthy women. Surgery carries risks of anxiety, injury, and time out of work, as well as a small risk of serious complications; it is also expensive.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      SCREENING TESTS FOR HIGH RISK WOMEN",
"     </span>",
"    </p>",
"    <p>",
"     Studies are being done to find the best combination of screening tests for ovarian cancer. Tests that may be useful for women at high risk of ovarian cancer include a blood test of the CA 125 tumor marker, ultrasonography, or a combination of the two.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      CA 125 tumor marker",
"     </span>",
"     &nbsp;&mdash;&nbsp;CA 125 is a protein that is higher than normal in approximately 80 percent of women with ovarian cancer. It can be measured with a blood test. CA 125 is commonly used to monitor women with ovarian cancer.",
"    </p>",
"    <p>",
"     It was hoped that CA 125 could be used to know if a woman was at risk for ovarian cancer. However, CA 125 levels can be high with a variety of other conditions, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Endometriosis",
"      </li>",
"      <li>",
"       Uterine fibroids",
"      </li>",
"      <li>",
"       Liver disease (cirrhosis)",
"      </li>",
"      <li>",
"       Pelvic infections",
"      </li>",
"      <li>",
"       Other cancers, including endometrial, breast, lung, and pancreatic cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Also, CA 125 levels are higher than normal in about 1 percent of healthy women, and the levels change during the menstrual cycle.",
"    </p>",
"    <p>",
"     So if you have a higher than normal CA 125 level, you could have ovarian cancer or a more common and less serious condition. Pelvic ultrasound may be helpful to know if you have ovarian cancer, although the only way to know for sure if you have ovarian cancer is to have surgery. As a result, CA 125 is not recommended as a stand-alone screening test for ovarian cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Pelvic ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pelvic ultrasound uses sound waves to create an image of the organs in the pelvis, including the ovaries. The test usually involves using an ultrasound wand on the abdomen and inside the vagina.",
"    </p>",
"    <p>",
"     When used as a screening test for ovarian cancer, vaginal ultrasound can find between 80 and 100 percent of ovarian cancers. However, ultrasound cannot always tell the difference between ovarian cancer and other more common conditions (ovarian cyst, endometriosis). False positive ultrasound tests (abnormal tests that do not indicate) may lead to more testing or unnecessary surgery to further evaluate the ovary. As a result, pelvic ultrasound is not recommended as a stand-alone screening test for ovarian cancer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Combined CA 125 and pelvic ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several studies have looked at using CA 125 and pelvic ultrasound together to detect ovarian cancer. However, the results of these studies have been somewhat disappointing:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Many women had unnecessary surgery because of false positive test results (the CA 125 or pelvic ultrasound was abnormal but no cancer was found).",
"      </li>",
"      <li>",
"       Some studies of CA 125 and pelvic ultrasound have found more cancers at an early, more treatable stage, while others have not. No published studies have shown that these tests reduce the risk of dying of ovarian cancer.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      WHO SHOULD BE SCREENED?",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      High risk family history",
"     </span>",
"     &nbsp;&mdash;&nbsp;A woman with a \"high-risk\" family history is someone who has a strong family history of breast or ovarian cancer in more than one relative or has family members with cancer who have certain characteristics.",
"    </p>",
"    <p>",
"     Women with this history should meet with a genetic counselor to discuss genetic testing for BRCA1 and BRCA2 (",
"     <a class=\"graphic graphic_table graphicRef57434 \" href=\"UTD.htm?27/17/27931\">",
"      table 1",
"     </a>",
"     ). Genetic testing is discussed in a separate article. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"      \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Ovarian cancer screening may be recommended if you have a high risk family history of ovarian cancer and:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       You have a BRCA mutation and you have your ovaries",
"      </li>",
"      <li>",
"       You have Lynch syndrome (also called hereditary nonpolyposis colorectal cancer [HNPCC]) and you have your ovaries",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Ovarian cancer screening may also be considered for women who are eligible to have genetic testing (because of their high-risk family history) but who have chosen not to have genetic testing. In this group, ovarian cancer screening may be recommended, starting at age 30 to 35, or 5 to 10 years earlier than the age when the youngest family member was diagnosed. Screening may include a blood test for CA-125 and a pelvic ultrasound.",
"    </p>",
"    <p>",
"     If you have a high risk family history, there are alternatives to ovarian cancer screening, such as having your ovaries removed to prevent cancer. These options are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link&amp;anchor=H8#H8\">",
"      \"Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)\", section on 'Interpreting the results'",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Lower risk family history",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women who do not meet the criteria for a high-risk family history should discuss their risks for ovarian cancer with a healthcare provider. Ovarian cancer screening is not usually recommended for this group.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Average risk women",
"     </span>",
"     &nbsp;&mdash;&nbsp;Women with an \"average risk\" of ovarian cancer do not have a personal or family history of ovarian cancer. Screening for ovarian cancer is not recommended in average risk women.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      SYMPTOMS OF OVARIAN CANCER",
"     </span>",
"    </p>",
"    <p>",
"     During the early stages of ovarian cancer, symptoms are often vague and ill-defined. Symptoms may include pelvic or abdominal discomfort, bloating, difficulty eating or feeling full, increased abdominal size, or rushing to urinate frequently. However, these symptoms can also be caused by many other conditions.",
"    </p>",
"    <p>",
"     If you have developed one or more of these symptoms in the past year, see your doctor or nurse. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"      \"Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"      \"Early detection of epithelial ovarian cancer: Role of symptom recognition\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H170272897\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169189\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/14/27874?source=see_link\">",
"      Patient information: Ovarian cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11283?source=see_link\">",
"      Patient information: Ovarian cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/63/10227?source=see_link\">",
"      Patient information: Cancer screening (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/27/39346?source=see_link\">",
"      Patient information: Ovarian cysts (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/26/27043?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11169173\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11252?source=see_link\">",
"      Patient information: Ovarian cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/34/41507?source=see_link\">",
"      Patient information: First-line medical treatment of epithelial ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/15/30963?source=see_link\">",
"      Patient information: Genetic testing for breast and ovarian cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23927?source=see_link\">",
"      Early detection of epithelial ovarian cancer: Role of symptom recognition",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/0/17418?source=see_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"      Screening for ovarian cancer",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Cancer Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cancer.gov/cancertopics/pdq/screening/ovarian/patient/\">",
"      www.cancer.gov/cancertopics/pdq/screening/ovarian/patient/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Medline Plus",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000889.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000889.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?6/15/6386/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 8, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?6/15/6386?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6386/abstract/1\">",
"      Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol 2006; 49:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6386/abstract/2\">",
"      Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6386/abstract/3\">",
"      Moore RG, MacLaughlan S, Bast RC Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol 2010; 116:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6386/abstract/4\">",
"      Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011; 305:2295.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f6_15_6386=[""].join("\n");
var outline_f6_15_6386=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           AM I AT RISK FOR OVARIAN CANCER?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           RISKS AND BENEFITS OF SCREENING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           SCREENING TESTS FOR HIGH RISK WOMEN",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           WHO SHOULD BE SCREENED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           SYMPTOMS OF OVARIAN CANCER",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?27/17/27931\" title=\"table 1\">",
"           BRCA testing USPSTF guidelines",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6387="Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)";
var content_f6_15_6387=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?31/14/31970\">",
"         Patient information: Dementia (including Alzheimer disease) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/35/11827\">",
"         Patient information: Diet and health (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/13/7379\">",
"         Patient information: Health and nutrition for women who breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?37/1/37907\">",
"         Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/59/41906\">",
"         Patient information: Nutrition before and during pregnancy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?14/37/14934\">",
"         Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28642\">",
"         Patient information: Diet and health (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/54/31588\">",
"         Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vitamin B12 deficiency and folate (folic acid) deficiency (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vitamin-b12-deficiency-and-folate-folic-acid-deficiency-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28578450\">",
"      <span class=\"h1\">",
"       What are vitamin B12 deficiency and folic acid deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vitamin B12 and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      (also called &ldquo;folate&rdquo;) are 2 different vitamins that your body needs to work normally. A &ldquo;deficiency&rdquo; means that your body does not have as much of something as it needs.",
"     </p>",
"     <p>",
"      People can have vitamin B12 deficiency,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency, or both.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578465\">",
"      <span class=\"h1\">",
"       Why are vitamin B12 and folic acid important?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your body needs vitamin B12 for many things. For example, you need vitamin B12 to make new cells, such as red blood cells, and for your nervous system to work normally.",
"     </p>",
"     <p>",
"      Your body needs",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      , too, to make new cells. It is especially important that pregnant women get enough folic acid, so that their baby can develop normally in the womb. Unborn babies need folic acid so that parts of their nervous system form correctly.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578480\">",
"      <span class=\"h1\">",
"       What causes vitamin B12 deficiency or folic acid deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People can get vitamin B12 or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency when:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        They don&rsquo;t eat enough foods that have vitamin B12 or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        in them.",
"       </li>",
"       <li>",
"        They eat foods with vitamin B12 and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        , but their body can&rsquo;t absorb or use the vitamins normally. These things can happen with certain medical problems or as a side effect of certain medicines.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578495\">",
"      <span class=\"h1\">",
"       What are the symptoms of vitamin B12 deficiency and folic acid deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A deficiency of vitamin B12,",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      , or both can cause anemia. Anemia is the term doctors use when a person has too few red blood cells. Anemia can cause headaches or make people feel tired or weak.",
"     </p>",
"     <p>",
"      A vitamin B12 deficiency can also cause other symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tingling or numbness in the hands or feet",
"       </li>",
"       <li>",
"        Trouble walking",
"       </li>",
"       <li>",
"        Mood changes",
"       </li>",
"       <li>",
"        Memory problems or trouble thinking clearly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578510\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should see your doctor or nurse if you have any of the symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578525\">",
"      <span class=\"h1\">",
"       Is there a test for vitamin B12 deficiency and folic acid deficiency?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse can do blood tests to check for deficiencies of these vitamins.",
"     </p>",
"     <p>",
"      If you have vitamin B12 or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency, your doctor or nurse will want to know why. He or she might do other tests to find out if it&rsquo;s because of a medical condition or a problem with your diet.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578540\">",
"      <span class=\"h1\">",
"       How are vitamin B12 deficiency and folic acid deficiency treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat vitamin B12 deficiency by giving people vitamin B12. The treatment comes as a shot or as pills. Most people with vitamin B12 deficiency need vitamin B12 shots, especially at first. Later, you might be able to take vitamin B12 pills instead of getting shots.",
"     </p>",
"     <p>",
"      Doctors treat",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency by giving people folic acid. This treatment comes as a pill.",
"     </p>",
"     <p>",
"      Your doctor or nurse will also treat the cause of your deficiency, if it can be treated. If you need help changing your diet, your doctor or nurse might recommend that you work with a dietitian (food expert).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578555\">",
"      <span class=\"h1\">",
"       Can vitamin B12 deficiency and folic acid deficiency be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can lower your chances of getting vitamin B12 deficiency and",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency by eating foods that have the vitamins in them.",
"     </p>",
"     <p>",
"      Foods with a lot of vitamin B12 include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Red meat",
"       </li>",
"       <li>",
"        Fish and shellfish",
"       </li>",
"       <li>",
"        Dairy foods",
"       </li>",
"       <li>",
"        Breakfast cereals that have vitamin B12 added to them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Foods with a lot of",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Green leafy vegetables",
"       </li>",
"       <li>",
"        Oranges and orange juice",
"       </li>",
"       <li>",
"        Breakfast cereals that have",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"         folic acid",
"        </a>",
"        added to them",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you don&rsquo;t eat these foods, your doctor or nurse might recommend that you take a vitamin supplement. Vitamin supplements are pills, capsules, or liquids that have nutrients in them.",
"     </p>",
"     <p>",
"      If you are a &ldquo;pure&rdquo; vegetarian and do not eat any meats, dairy foods, or eggs, you will not get enough vitamin B12 from your diet alone. To avoid getting a vitamin B12 deficiency, you will need to take a vitamin B12 supplement or eat foods with vitamin B12 added to them.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578570\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to get pregnant, you should start taking a multivitamin at least 1 month before you start trying to get pregnant. Choose a &ldquo;prenatal&rdquo; multivitamin that has at least 400 micrograms of",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"       folic acid",
"      </a>",
"      . Show your doctor or nurse the vitamin you plan to take to make sure the doses are right for you and your baby. Too much of some vitamins can be harmful.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28578585\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=see_link\">",
"       Patient information: Diet and health (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=see_link\">",
"       Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=see_link\">",
"       Patient information: Health and nutrition for women who breastfeed (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41906?source=see_link\">",
"       Patient information: Nutrition before and during pregnancy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=see_link\">",
"       Patient information: Diet and health (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=see_link\">",
"       Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=see_link\">",
"       Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?6/15/6387?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17169 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-01FC61200C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6387=[""].join("\n");
var outline_f6_15_6387=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578450\">",
"      What are vitamin B12 deficiency and folic acid deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578465\">",
"      Why are vitamin B12 and folic acid important?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578480\">",
"      What causes vitamin B12 deficiency or folic acid deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578495\">",
"      What are the symptoms of vitamin B12 deficiency and folic acid deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578510\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578525\">",
"      Is there a test for vitamin B12 deficiency and folic acid deficiency?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578540\">",
"      How are vitamin B12 deficiency and folic acid deficiency treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578555\">",
"      Can vitamin B12 deficiency and folic acid deficiency be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578570\">",
"      What if I want to get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28578585\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/14/31970?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28642?source=related_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/35/11827?source=related_link\">",
"      Patient information: Diet and health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/1/37907?source=related_link\">",
"      Patient information: How to plan and prepare for a healthy pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/54/31588?source=related_link\">",
"      Patient information: Maternal health and nutrition during breastfeeding (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?40/59/41906?source=related_link\">",
"      Patient information: Nutrition before and during pregnancy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6388="Methscopolamine: Patient drug information";
var content_f6_15_6388=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Methscopolamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/45/17108?source=see_link\">",
"     see \"Methscopolamine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F194809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pamine&reg;;",
"     </li>",
"     <li>",
"      Pamine&reg; Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F194810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Pamine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691855",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat GI (gastrointestinal) ulcers.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to methscopolamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Bleeding problems, enlarged colon, a fast heartbeat, glaucoma, bowel block, myasthenia gravis, reflux esophagitis, very bad ulcerative colitis, slow-moving GI (gastrointestinal) tract, or trouble passing urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man with problems passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 30 minutes before meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11794 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6388=[""].join("\n");
var outline_f6_15_6388=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194809\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F194810\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014425\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014424\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014429\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014430\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014432\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014427\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014428\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014433\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014434\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/45/17108?source=related_link\">",
"      Methscopolamine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6389="Cyproterone: Patient drug information";
var content_f6_15_6389=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cyproterone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=see_link\">",
"     see \"Cyproterone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Androcur&reg;;",
"     </li>",
"     <li>",
"      Androcur&reg; Depot;",
"     </li>",
"     <li>",
"      Novo-Cyproterone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692030",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat prostate cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701877",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cyproterone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Kidney disease or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a woman.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697992",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lowered night eyesight. Use care when driving or doing other tasks that call for clear eyesight. Keep work space well lit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breast soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698706",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are planning to harm yourself or the want to harm yourself gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696559",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11709 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.69.132.100-4DCBBA35C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6389=[""].join("\n");
var outline_f6_15_6389=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155793\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028657\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028656\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028661\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028662\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028664\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028659\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028660\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028665\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028666\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/2/14374?source=related_link\">",
"      Cyproterone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6390="Raloxifene: Drug information";
var content_f6_15_6390=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Raloxifene: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/42/18085?source=see_link\">",
"    see \"Raloxifene: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F217082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Evista&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F217083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Raloxifene&reg;;",
"     </li>",
"     <li>",
"      Evista&reg;;",
"     </li>",
"     <li>",
"      Novo-Raloxifene;",
"     </li>",
"     <li>",
"      Teva-Raloxifene",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F217113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Selective Estrogen Receptor Modulator (SERM)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F217087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis:",
"     </b>",
"     Females: Oral: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Invasive breast cancer risk reduction:",
"     </b>",
"     Female: Oral: 60 mg once daily for 5 years per ASCO guidelines (Visvanathan, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F217088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9219197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Moderate-to-severe impairment: Use caution; safety and efficacy have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F217089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild impairment (Child-Pugh class A): Plasma concentrations were higher and correlated with total bilirubin. Safety and efficacy in hepatic insufficiency have not been established.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F217060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Evista&reg;: 60 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F217046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7885625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088593.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088593.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2930855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F217062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of osteoporosis in postmenopausal women; risk reduction for invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women with high risk for invasive breast cancer",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F217119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Evista&reg; may be confused with AVINza&reg;, Eovist&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Raloxifene may be confused with ospemifene, toremifene",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F217111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Raloxifene has been associated with increased risk of thromboembolism (DVT, PE) and superficial thrombophlebitis; risk is similar to reported risk of HRT",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (3% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (8% to 29%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (11% to 16%), leg cramps/muscle spasm (6% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu syndrome (14% to 15%), infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (3%), venous thromboembolism (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Insomnia (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Weight gain (9%), abdominal pain (7%), vomiting (5%), flatulence (2% to 3%), cholelithiasis (&le;3%), gastroenteritis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal bleeding (6%), leukorrhea (3%), urinary tract disorder (3%), uterine disorder (3%), vaginal hemorrhage (3%), endometrial disorder (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (8%), tendon disorder (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (10%), sinusitis (10%), pharyngitis (8%), pneumonia (3%), laryngitis (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Apolipoprotein A-1 increased, apolipoprotein B decreased, death related to VTE, fibrinogen decreased, hypertriglyceridemia (in women with a history of increased triglycerides in response to oral estrogens), intermittent claudication, LDL cholesterol decreased, lipoprotein decreased, retinal vein occlusion, stroke related to VTE, superficial thrombophlebitis, total serum cholesterol decreased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F217065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of or current venous thromboembolic disorders (including DVT, PE, and retinal vein thrombosis); pregnancy or women who could become pregnant; breast-feeding",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F217050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: May increase the risk for DVT or PE; use contraindicated in patients with history of or current venous thromboembolic disorders.",
"     </b>",
"     Use with caution in patients at high risk for venous thromboembolism; consider risk vs benefit in women at risk for thromboembolism (HF, superficial thrombophlebitis, malignancy). The risk for DVT and PE are higher during the first 4 months of treatment. Superficial thrombophlebitis has also been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: The risk of death due to stroke may be increased in women with coronary heart disease or in women at risk for coronary events;",
"     </b>",
"     use with caution in patients with cardiovascular disease. Do not use for the prevention of cardiovascular disease. Risk vs benefit should be considered in women at risk for stroke (eg, prior stroke, TIA, atrial fibrillation, hypertension, or smokers).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Women with a history of elevated triglycerides in response to treatment with oral estrogens (or estrogen/progestin) may develop elevated triglycerides when treated with raloxifene; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with moderate-to-severe renal impairment; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Uterine bleeding: Investigate unexplained uterine bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Estrogens: Use with systemic estrogen therapy is not recommended; safety has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Males: Safety and efficacy have not been established in men.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal women: Safety has not been established in premenopausal women; not indicated in premenopausal women.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not indicated for treatment of invasive breast cancer, to reduce the risk of recurrence of invasive breast cancer, or to reduce the risk of noninvasive breast cancer. The efficacy (for breast cancer risk reduction) in women with inherited BRCA1 and BRCA1 mutations has not been established. Any breast abnormality during treatment should be investigated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prolonged immobilization: Discontinue at least 72 hours prior to and during prolonged immobilization (postoperative recovery or prolonged bedrest); restart only once patient fully ambulatory. Advise patients to move periodically during prolonged travel. The NCCN breast cancer risk reduction guidelines (v.2.2009) recommend stopping raloxifene 2-4 weeks prior to elective surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F217055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Raloxifene.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Raloxifene may decrease the absorption of Levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Selective Estrogen Receptor Modulators may enhance the adverse/toxic effect of Ospemifene. Ospemifene may also enhance adverse/toxic effects of other Selective Estrogen Receptor Modulators. Selective Estrogen Receptor Modulators may diminish the therapeutic effect of Ospemifene. Ospemifene may also diminish the therapeutic effects of other Selective Estrogen Receptor Modulators.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F217078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F217056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F217069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenicity and fetal loss. There are no adequate and well-controlled studies in pregnant women. Raloxifene should not be used by women who are or may become pregnant.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F217093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2930854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     May be taken without regard to meals. Osteoporosis prevention or treatment: Ensure adequate calcium and vitamin D intake; postmenopausal women should consume ~1500 mg/day of elemental calcium and 400-800 units/day of vitamin D.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F217068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Evista Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (100): $655.80",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F217058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Bone mineral density (BMD), lipid profile; adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F217070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bonmax (IN);",
"     </li>",
"     <li>",
"      Celvista (TH);",
"     </li>",
"     <li>",
"      Evista (AR, AT, AU, BE, BF, BG, BJ, BR, CH, CI, CL, CN, CO, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HN, ID, IE, IL, IT, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, PE, PH, PK, PL, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, TN, TR, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Loxar (UY);",
"     </li>",
"     <li>",
"      Loxifen (PY);",
"     </li>",
"     <li>",
"      Optruma (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, SE, SK, TR);",
"     </li>",
"     <li>",
"      Raloxiqueen (KP);",
"     </li>",
"     <li>",
"      Raxeto (AR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F217049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A selective estrogen receptor modulator (SERM), meaning that it affects some of the same receptors that estrogen does, but not all, and in some instances, it antagonizes or blocks estrogen; it acts like estrogen to prevent bone loss and has the potential to block some estrogen effects in the breast and uterine tissues. Raloxifene decreases bone resorption, increasing bone mineral density and decreasing fracture incidence.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F217064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid; ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 2348 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;95% to albumin and &alpha;-glycoprotein; does not bind to sex-hormone-binding globulin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, extensive first-pass effect; metabolized to glucuronide conjugates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~2%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 28-33 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces; urine (&lt;0.2% as unchanged drug; &lt;6% as glucuronide conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barrett-Connor E, Mosca L, Collins P, et al, &ldquo;Raloxifene Use for The Heart (RUTH) Trial Investigators. Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(2):125-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/16837676/pubmed\" id=\"16837676\" target=\"_blank\">",
"        16837676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Col N, Winer EP, et al, &ldquo;American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(15):3328-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/12149307/pubmed\" id=\"12149307\" target=\"_blank\">",
"        12149307",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cummings SR, Eckert S, Krueger KA, et al, &ldquo;The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results from the MORE Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1999, 281(23) 2189-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/9676687/pubmed\" id=\"9676687\" target=\"_blank\">",
"        9676687",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al, &ldquo;Effects of Raloxifene on Bone Mineral Density, Serum Cholesterol Concentrations, and Uterine Endometrium in Postmenopausal Women,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(23):1641-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/9385122/pubmed\" id=\"9385122\" target=\"_blank\">",
"        9385122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Draper MW, Flowers DE, Huster WJ, et al, &ldquo;A Controlled Trial of Raloxifene (LY139481) HCl: Impact on Bone Turnover and Serum Lipid Profile in Healthy Postmenopausal Women,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 1996, 11(6):835-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/8725181/pubmed\" id=\"8725181\" target=\"_blank\">",
"        8725181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heaney RP and Draper MW, &ldquo;Raloxifene and Estrogen: Comparative Bone-Remodeling Kinetics,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1997, 2(10):3425-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Land SR, Wickerham DL, Costantino JP, et al, &ldquo;Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(23):2742-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/16754728/pubmed\" id=\"16754728\" target=\"_blank\">",
"        16754728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Martino S, Cauley JA, Barrett-Connor E, et al, &ldquo;Continuing Outcomes Relevant to Evista: Breast Cancer Incident in Postmenopausal Women in a Randomized Trial of Raloxifene,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2004, 96(23):1751-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/15572757/pubmed\" id=\"15572757\" target=\"_blank\">",
"        15572757",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer,&rdquo; Version 1.2009. Available at  file://www.nccn.org/professionals/physician_gls/PDF/breast.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Breast Cancer Risk Reduction,&rdquo;  Version 2.2009. Available at file://www.nccn.org/professionals/physician_gls/PDF/breast_risk.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siris ES, Harrris ST, Eastell R, et al, &ldquo;Skeletal Effects of Raloxifene After 8 Years: Results From the Continuing Outcomes Relevant to Evista (CORE) Study,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2005, 20(9):1514-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/16059623/pubmed\" id=\"16059623\" target=\"_blank\">",
"        16059623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Visvanathan K, Chlebowski RT, Hurley P, et al, &ldquo;American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(19):3235-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/19470930/pubmed\" id=\"19470930\" target=\"_blank\">",
"        19470930",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vogel VG, Costantino JP, Wickerham DL, &ldquo;Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(23):2727-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6390/abstract-text/16754727/pubmed\" id=\"16754727\" target=\"_blank\">",
"        16754727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9593 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6390=[""].join("\n");
var outline_f6_15_6390=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709396\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217082\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217083\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217113\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217087\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217088\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9219197\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217089\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217060\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217046\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885625\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930855\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217062\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217119\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217111\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217065\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217050\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299977\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217055\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217078\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217056\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217069\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217093\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2930854\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217068\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217058\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217070\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217049\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F217064\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9593\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9593|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/42/18085?source=related_link\">",
"      Raloxifene: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6391="Polistes dominula worker";
var content_f6_15_6391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F64729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F64729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polistes dominula worker",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nancy Bresich, PhD and Albert Greene, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6391=[""].join("\n");
var outline_f6_15_6391=null;
var title_f6_15_6392="Abciximab: Drug information";
var content_f6_15_6392=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Abciximab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/52/11076?source=see_link\">",
"    see \"Abciximab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F128991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Reopro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F128992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ReoPro&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F128994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Percutaneous coronary intervention (PCI):",
"     </b>",
"     I.V.: 0.25 mg/kg bolus administered 10-60 minutes prior to start of PCI followed by an infusion of 0.125 mcg/kg/minute (maximum: 10 mcg/minute) for 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Unstable angina/non-ST-elevation MI (UA/NSTEMI) unresponsive to conventional medical therapy with planned PCI within 24 hours:",
"     </b>",
"     I.V.: 0.25 mg/kg bolus followed by an 18- to 24-hour infusion of 10 mcg/minute, concluding 1 hour after PCI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) (unlabeled use; Kushner, 2009):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Loading dose: 0.25 mg/kg bolus administered at the time of PCI",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance infusion: 0.125 mcg/kg/minute (maximum: 10 mcg/minute) continued for up to 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F128995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15671238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15671239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F128975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reopro&reg;: 2 mg/mL (5 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F128960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F128978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Abciximab is intended for coadministration with aspirin postangioplasty and heparin infused and weight adjusted to maintain a therapeutic bleeding time (eg, ACT 300-500 seconds). Solution must be filtered prior to administration. Do not shake the vial.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14471247\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     7.2 mg in 250 mL (concentration: 28.8",
"     <b>",
"      mcg",
"     </b>",
"     /mL)",
"     <b>",
"      or",
"     </b>",
"     9 mg in 250 mL (concentration: 36",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F129030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS. Abciximab should be administered in a separate intravenous line. No incompatibilities have been observed with glass bottles or PVC bags.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Adenosine, argatroban, atropine, bivalirudin, diphenhydramine, fentanyl, metoprolol, midazolam.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Tenecteplase.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F128976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention (PCI); prevention of cardiac ischemic complications in patients with unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI) unresponsive to conventional therapy when PCI is scheduled within 24 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Intended for use with aspirin and heparin, at a minimum.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F1962643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To support PCI during ST-elevation myocardial infarction (STEMI) (administered at the time of primary PCI)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As with all drugs which may affect hemostasis, bleeding is associated with abciximab. Hemorrhage may occur at virtually any site. Risk is dependent on multiple variables, including the concurrent use of multiple agents which alter hemostasis and patient susceptibility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (14.4%), chest pain (11.4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (13.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Minor bleeding (4.0% to 16.8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (17.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (4.5%), peripheral edema (1.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (6.45)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (7.3%), abdominal pain (3.1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Major bleeding (1.1% to 14%), thrombocytopenia: &lt;100,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     (2.5% to 5.6%); &lt;50,000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     (0.4% to 1.7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (3.6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal thinking, allergic reactions/anaphylaxis (possible), AV block, bronchospasm, bullous eruption, coma, confusion, diabetes mellitus, embolism, hyperkalemia, ileus, inflammation, intracranial hemorrhage, myalgia, nodal arrhythmia, pleural effusion, pulmonary embolism, prostatitis, pruritus, stroke, urinary retention, ventricular tachycardia, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F128981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to abciximab, murine proteins, or any component of the formulation; active internal hemorrhage or recent (within 6 weeks) clinically-significant GI or GU bleeding; history of cerebrovascular accident within 2 years or  with significant neurological deficit; clotting abnormalities or administration of oral anticoagulants within 7 days unless prothrombin time (PT) is &le;1.2 times control PT value; thrombocytopenia (&lt;100,000 cells/&mu;L); recent (within 6 weeks) major surgery or trauma; intracranial tumor, arteriovenous malformation, or aneurysm; severe uncontrolled hypertension; history of vasculitis; use of dextran before PTCA or intent to use dextran during PTCA; concomitant use of another parenteral GP IIb/IIIa inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F128964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Administration may result in human antichimeric antibody formation that can cause hypersensitivity reactions (including anaphylaxis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; watch closely for bleeding, especially the arterial access site for the cardiac catheterization. Use with extreme caution in patients with platelet counts &lt;150,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , patients with hemorrhagic retinopathy, previous history of GI disease, recent thrombolytic therapy and in chronic dialysis patients. Use caution with administration of other drugs affecting hemostasis. Minimize other procedures including arterial and venous punctures, I.M. injections, nasogastric tubes, etc. Increased risk of hemorrhage during or following angioplasty is associated with unsuccessful PTCA, PTCA procedure &gt;70 minutes duration, or PTCA performed within 12 hours of symptom onset for acute myocardial infarction. When attempting I.V. access, avoid noncompressible sites (eg, subclavian or jugular veins).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Administration may result in human antichimeric antibody formation that can cause thrombocytopenia; readministration within 30 days or in patients with human antichimeric antibodies (HACA) increases the incidence and severity of thrombocytopenia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in patients &gt;65 years of age; increased risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Low weight patients: Use with caution in patients weighing &lt;75 kg; increased risk of bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diminished efficacy: Administration may result in human antichimeric antibody formation that can cause diminished efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sheath removal: Prior to pulling the sheath, heparin should be discontinued for 3-4 hours and ACT &le;175 seconds or aPTT &le;50 seconds. Use standard compression techniques after sheath removal. Watch the site closely afterwards for further bleeding.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F128969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextran: May enhance the anticoagulant effect of Abciximab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Monoclonal Antibodies: Abciximab may enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F128971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F128983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"     <i>",
"      In vitro",
"     </i>",
"     studies have shown only small amounts of abciximab to cross the placenta. It is not known whether abciximab can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F128999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (ReoPro Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/mL (5 mL): $983.40",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F128973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prothrombin time, activated partial thromboplastin time (aPTT), hemoglobin, hematocrit, platelet count, fibrinogen, fibrin split products, transfusion requirements, signs of hypersensitivity reactions, guaiac stools, Hemastix&reg; urine. Platelet count should be monitored at baseline, 2-4 hours following bolus infusion, and at 24 hours (or prior to discharge, if before 24 hours). To minimize risk of bleeding:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Abciximab initiated 18-24 hours prior to PCI: Maintain aPTT between 60-85 seconds during the heparin/abciximab infusion period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     During PCI: Maintain ACT between 200-300 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Following PCI (if anticoagulation is maintained): Maintain aPTT between 50-75 seconds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sheath removal should not occur until aPTT is &le;50 seconds or ACT &le;175 seconds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maintain bleeding precautions, avoid unnecessary arterial and venous punctures, use saline or heparin lock for blood drawing, assess sheath insertion site and distal pulses of affected leg every 15 minutes for the first hour and then every 1 hour for the next 6 hours. Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bedrest with the head of the bed at a 30&deg; angle and the affected limb restrained in a straight position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Observe patient for mental status changes, hemorrhage; assess nose and mouth mucous membranes, puncture sites for oozing, ecchymosis, and hematoma formation; and examine urine, stool, and emesis for presence of occult or frank blood; gentle care should be provided when removing dressings.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F128984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Clotinab (TH);",
"     </li>",
"     <li>",
"      ReoPro (AR, AT, AU, BE, BG, BR, CH, CN, CO, CZ, DE, DK, ES, FI, FR, GB, GR, HK, IE, IL, IN, IT, KP, LU, MX, MY, NL, NO, NZ, PE, PK, PL, PT, RU, SE, SG, TH, TW, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F128963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fab antibody fragment of the chimeric human-murine monoclonal antibody 7E3; this agent binds to platelet IIb/IIIa receptors, resulting in steric hindrance, thus inhibiting platelet aggregation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F128980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Rapid; platelet aggregation reduced to &lt;20% of baseline at 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Up to 72 hours for restoration of normal hemostasis (Schror, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.07 L/kg (Schror, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Mostly bound to GP IIb/IIIa receptors on platelet surface",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Unbound abciximab metabolized via proteolytic cleavage (Schror, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Plasma: ~30 minutes; dissociation half-life from GP IIb/IIIa receptors: up to 4 hours (Schror, 2003).",
"     <b>",
"      Note:",
"     </b>",
"     29% and 13% of abciximab estimated to remain on GP IIb/IIIa receptors at 8 and 15 days, respectively (Mascelli, 1998). Platelet function may remain abnormal for up to 7 days post infusion (Osende, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Platelet inhibition: ~30 minutes (Mascelli, 1998)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2007, 116(7):e148-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/17679616/pubmed\" id=\"17679616\" target=\"_blank\">",
"        17679616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aguirre FV, Topol EJ, and Ferguson JJ, &ldquo;Bleeding Complications With the Chimeric Antibody to Platelet Glycoprotein IIb/IIIa Intergrin in Patients Undergoing Percutaneous Coronary Intervention. EPIC Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1995, 91(12):2882-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/7796496/pubmed\" id=\"7796496\" target=\"_blank\">",
"        7796496",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Giugliano RP, Gibson CM, et al, &ldquo;Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(21):2720-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10351964/pubmed\" id=\"10351964\" target=\"_blank\">",
"        10351964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;ASSENT-3 Investigators. Efficacy and Safety of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: The ASSENT-3 Randomised Trial in Acute Myocardial Infarction,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 358 (9282):605-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/11530146/pubmed\" id=\"11530146\" target=\"_blank\">",
"        11530146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berkowitz SD, Harrington RA, Rund MM, et al, &ldquo;Acute Profound Thrombocytopenia After C7E3 Fab (Abciximab) Therapy,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1997, 95(4):809-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9054735/pubmed\" id=\"9054735\" target=\"_blank\">",
"        9054735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brener SJ, Barr LA, Burchenal JE, et al, &ldquo;Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,&rdquo; ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators,",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 98(8):734-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ellis SG, Tendera M, de Belder MA, et al, &ldquo;Facilitated PCI in Patients With ST-Elevation Myocardial Infarction,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 358(21):2205-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/18499565/pubmed\" id=\"18499565\" target=\"_blank\">",
"        18499565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giugliano RP, &ldquo;Drug-Induced Thrombocytopenia: Is It a Serious Concern for Glycoprotein IIb/IIIa Receptor Inhibitors?&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 1998, 5(3):191-202.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10767115/pubmed\" id=\"10767115\" target=\"_blank\">",
"        10767115",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamm CW, Heeschen C, Goldmann B, et al, &ldquo;Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(21):1623-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10341274/pubmed\" id=\"10341274\" target=\"_blank\">",
"        10341274",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huxtable LM, Tafreshi MJ, and Rakkar AN, &ldquo;Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2006, 97(3):426-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/16442410 /pubmed\" id=\"16442410 \" target=\"_blank\">",
"        16442410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jubelirer SJ, Koenig BA, and Bates MC, &ldquo;Acute Profound Thrombocytopenia Following C7E3 Fab (Abciximab) Therapy: Case Reports, Review of the Literature and Implications for Therapy,&rdquo;",
"      <i>",
"       Am J Hematol",
"      </i>",
"      , 1999, 61(3):205-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10398314/pubmed\" id=\"10398314\" target=\"_blank\">",
"        10398314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kastrati A, Mehilli J, Neumann FJ, et al, &ldquo;Abciximab in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2006, 295(3):1531-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/16533938/pubmed\" id=\"16533938\" target=\"_blank\">",
"        16533938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keeley EC, Boura JA, and Grines CL, &ldquo;Comparison of Primary and Facilitated Percutaneous Coronary Interventions for ST-elevation Myocardial Infarction: Quantitative Review of Randomised Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9510):579-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/16488801/pubmed\" id=\"16488801\" target=\"_blank\">",
"        16488801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al, &ldquo;2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):172-209.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/18191745/pubmed\" id=\"18191745\" target=\"_blank\">",
"        18191745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kushner FG, Hand M, Smith SC, et al, &ldquo;2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(23):2205-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/19942100/pubmed\" id=\"19942100\" target=\"_blank\">",
"        19942100",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Anderson KM, et al, &ldquo;Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1997, 30(1):149-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9207636/pubmed\" id=\"9207636\" target=\"_blank\">",
"        9207636",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Moliterno DJ, et al, &ldquo;Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341(5):319-27.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10423466/pubmed\" id=\"10423466\" target=\"_blank\">",
"        10423466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Califf RM, Van de Werf F, et al, &ldquo;Mortality at 1 Year With Combination Platelet Glycoprotein IIb/IIIa Inhibition and Reduced-Dose Fibrinolytic Therapy vs Conventional Fibrinolytic Therapy for Acute Myocardial Infarction: GUSTO V Randomized Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(17):2130-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/12413372/pubmed\" id=\"12413372\" target=\"_blank\">",
"        12413372",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lincoff AM, Tcheng JE, Califf RM, et al, &ldquo;Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1999, 99(15):1951-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10208997/pubmed\" id=\"10208997\" target=\"_blank\">",
"        10208997",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Llevadot J, Coulter SA, and Giugliano RP, &ldquo;A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2000, 9(2):175-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10613999/pubmed\" id=\"10613999\" target=\"_blank\">",
"        10613999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mascelli MA, Lance ET, Damaraju L, et al, &ldquo;Pharmacodynamic Profile of Short-Term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery from GP IIb/IIIa Receptor Blockade,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1998, 97(17):1680-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9591761/pubmed\" id=\"9591761\" target=\"_blank\">",
"        9591761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moliterno DJ, Yakubov SJ, DiBattiste PM, et al, &ldquo;Outcomes at 6 months for the Direct Comparison of Tirofiban and Abciximab During Percutaneous Coronary Revascularization With Stent Placement: The TARGET Follow-up Study.&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9330):355-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/12241774/pubmed\" id=\"12241774\" target=\"_blank\">",
"        12241774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Osende JI, Fuster V, Lev EI, et al, &ldquo;Testing Platelet Activation With a Shear-Dependent Platelet Function Test Versus Aggregation-Based Tests: Relevance for Monitoring Long-Term Glycoprotein IIb/IIIa Inhibition,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 103(11):1488-91.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin During Percutaneous Coronary Revascularization. The EPILOG Investigators,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(24):1689-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9182212/pubmed\" id=\"9182212\" target=\"_blank\">",
"        9182212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Randomised Placebo-Controlled Trial of Abciximab Before and During Coronary Intervention in Refractory Unstable Angina: The CAPTURE Study,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 349(9063):1429-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9164316/pubmed\" id=\"9164316\" target=\"_blank\">",
"        9164316",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schr&ouml;r K and Weber A, &ldquo;Comparative Pharmacology of GP IIb/IIIa Antagonists,&rdquo;",
"      <i>",
"       J Thromb Thrombolysis",
"      </i>",
"      , 2003, 15(2):71-80",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/14618072/pubmed\" id=\"14618072\" target=\"_blank\">",
"        14618072",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinnaeve PR, Alexander JH, Bogaerts K, et al, \"Efficacy of Tenecteplase in Combination With Enoxaparin, Abciximab, or Unfractionated Heparin: One-Year Follow-Up Results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) Randomized Trial in Acute Myocardial Infarction,\"",
"      <i>",
"       Am Heart J",
"      </i>",
"      , 2004, 147:993-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/15199346/pubmed\" id=\"15199346\" target=\"_blank\">",
"        15199346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone GW, Maehara A, Witzenbichler B, et al, &ldquo;Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction: The INFUSE-AMI Randomized Trial,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 307(17):1817-26",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/22447888/pubmed\" id=\"22447888\" target=\"_blank\">",
"        22447888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tcheng JE, Kereiakes DJ, Lincoff AM, et al, &ldquo;Abciximab Readministration: Results of the ReoPro&reg; Readministration Registry,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2001, 104(8):870-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/11514371/pubmed\" id=\"11514371\" target=\"_blank\">",
"        11514371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Thiele H, W&ouml;hrle J, Hambrecht R, et al, &ldquo;Intracoronary Versus Intravenous Bolus Abciximab During Primary Percutaneous Coronary Intervention in Patients With Acute ST-elevation Myocardial Infarction: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2012, 379(9819):923-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/22357109/pubmed\" id=\"22357109\" target=\"_blank\">",
"        22357109",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, Ferguson JJ, Weisman HF, et al, &ldquo;Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta",
"      <sub>",
"       3",
"      </sub>",
"      Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 278(6):479-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9256222/pubmed\" id=\"9256222\" target=\"_blank\">",
"        9256222",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol EJ, GUSTO V Investigators, &ldquo;Reperfusion Therapy for Acute Myocardial Infarction With Fibrinolytic Therapy or Combination Reduced Fibrinolytic Therapy and Platelet Glycoprotein IIb/IIIa Inhibition: The GUSTO V Randomized Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9272):1905-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/11425410/pubmed\" id=\"11425410\" target=\"_blank\">",
"        11425410",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Topol E, Moliterno DJ, Herrmann HC, et al, &ldquo;Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events With Percutaneous Coronary Revascularization,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 244:1888-94.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trivedi SM, Shani J, and Hollander G, &ldquo;Bleeding Complications of Platelet Glycoprotein IIb/IIIa Inhibitor Abciximab (ReoPro&reg;),&rdquo;",
"      <i>",
"       J Invasive Cardiol",
"      </i>",
"      , 2002, 14(7):423-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/12082199/pubmed\" id=\"12082199\" target=\"_blank\">",
"        12082199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Use of a Monoclonal Antibody Directed Against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty. The EPIC Investigation,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(14):956-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/8121459/pubmed\" id=\"8121459\" target=\"_blank\">",
"        8121459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vahdat B, Canavy I, Fourcade L, et al, &ldquo;Fatal Cerebral Hemorrhage and Severe Thrombocytopenia During Abciximab Treatment,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2000, 49(2):177-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10642768/pubmed\" id=\"10642768\" target=\"_blank\">",
"        10642768",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Merkhof LF, Zijlstra F, Olsson H, et al, &ldquo;Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(6):1528-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/10334418/pubmed\" id=\"10334418\" target=\"_blank\">",
"        10334418",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wandt H, Frank M, Ehninger G, et al, &ldquo;Safety and Cost Effectiveness of a 10 X 10",
"      <sup>",
"       9",
"      </sup>",
"      /L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 X 10",
"      <sup>",
"       9",
"      </sup>",
"      /L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1998, 91(10):3601-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/15/6392/abstract-text/9572994/pubmed\" id=\"9572994\" target=\"_blank\">",
"        9572994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9204 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.80.101-F119FB24C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6392=[""].join("\n");
var outline_f6_15_6392=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128991\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128992\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129024\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128994\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128995\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671238\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15671239\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128975\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128960\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128978\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471247\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129030\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128976\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1962643\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174499\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129022\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128981\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128964\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298628\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128969\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128971\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128983\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128999\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322956\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128973\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128984\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128963\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F128980\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9204\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9204|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/52/11076?source=related_link\">",
"      Abciximab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6393="Intimate partner violence: Diagnosis and screening";
var content_f6_15_6393=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intimate partner violence: Diagnosis and screening",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Amy Weil, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6393/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/15/6393/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H8920143\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence (IPV) is a serious, preventable public health problem affecting more than 32 million Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/1\">",
"     1",
"    </a>",
"    ]. IPV affects both sexes but women are more often victims than men. Lifetime estimates for IPV involving women in the United States range from 22 to 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In countries around the world, 10 to 69 percent of women report physical assault by an intimate partner at some time in their life [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The term \"intimate partner violence\" describes actual or threatened psychological, physical, or sexual harm by a current or former partner or spouse. IPV can occur among heterosexual or same-sex couples and does not require sexual intimacy.",
"   </p>",
"   <p>",
"    All too frequently, IPV is undiagnosed since patients often conceal that they are in abusive relationships. The clues pointing to abuse may be subtle or absent. Many groups advocate screening all patients, or all female patients, for intimate partner violence.",
"   </p>",
"   <p>",
"    This topic will discuss the clinical presentation and diagnosis of intimate partner violence and issues related to population screening with recommendations of various groups. The epidemiology and health consequences of IPV and management of patients in whom IPV is identified are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=see_link\">",
"     \"Intimate partner violence: Intervention and patient management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920150\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Victims of intimate partner violence are found among people of all ages, socioeconomic classes, ethnicities, gender identities, and sexual preferences. While certain risk factors have been identified (younger age, female, lower socioeconomic status, family history or personal history of violence), IPV should be considered in all patients who present with a history or findings consistent with undisclosed violence. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link\">",
"     \"Intimate partner violence: Epidemiology and health consequences\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain aspects of the history or observations made during the clinical encounter should heighten the clinician's suspicion of IPV. These include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An inconsistent explanation of injuries.",
"     </li>",
"     <li>",
"      Delay in seeking treatment.",
"     </li>",
"     <li>",
"      Frequent emergency department or urgent visits. Typically abusers do not want their victims to form an ongoing allegiance with one physician. They may feel the victim will be less likely to find an ally in an emergency department where care may be more fragmented.",
"     </li>",
"     <li>",
"      Missed appointments. The patient may not keep appointments because the abuser will not allow medical attention. In one study, 17 percent of victims of IPV felt that their partner interfered with their access to provider visits, compared to 2 percent of those not suffering from abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/6\">",
"       6",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      For pregnant women, late initiation of prenatal care.",
"     </li>",
"     <li>",
"      Repeated abortions. Unplanned pregnancy may result from sexual assault",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      not being allowed to use birth control.",
"     </li>",
"     <li>",
"      Medication nonadherence. Victims may not take medicines because the batterer has taken them away or not allowed the partner to fill prescriptions.",
"     </li>",
"     <li>",
"      Inappropriate affect. Victims may appear jumpy, fearful, or cry readily. They may avoid eye contact and seem evasive or hostile. A flat affect or dissociated appearance may suggest posttraumatic stress disorder.",
"     </li>",
"     <li>",
"      Overly attentive or verbally abusive partner. The clinician should be suspicious if the partner is overly solicitous or answers questions for the patient. If the partner refuses to leave the examination room, the clinician should find a way to get the partner to leave before questioning the patient. Partner reluctance to leave the patient alone is an important sign.",
"     </li>",
"     <li>",
"      Apparent social isolation.",
"     </li>",
"     <li>",
"      Reluctance to undress, have a genital or rectal examination, or difficulty with these examinations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920157\">",
"    <span class=\"h2\">",
"     Common presenting complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intimate partner violence is associated with a perception of overall poor health. This was shown in a multi-country report, sponsored by the World Health Organization, based on surveys of women aged 15 to 49 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/7\">",
"     7",
"    </a>",
"    ]. Although confounding issues may account for some of the observed associations, violence is associated with difficulty in ambulation, difficulty with daily activities, memory loss, dizziness, emotional distress, and pelvic complaints.",
"   </p>",
"   <p>",
"    Gynecologic conditions that are seen more frequently in abused patients include premenstrual syndrome, sexually transmitted diseases including HIV infection, unintended pregnancy, and chronic pelvic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link\">",
"     \"Causes of chronic pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatic complaints associated with IPV include chronic pain, irritable bowel syndrome, headaches, and musculoskeletal pain.",
"   </p>",
"   <p>",
"    Psychological conditions associated with IPV include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression, suicidality (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anxiety and panic disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"       \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=see_link\">",
"       \"Panic disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eating disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Substance use (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=see_link\">",
"       \"Substance use disorders: Principles for recognition and assessment in general medical care\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Posttraumatic stress disorder (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"       \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dissociative disorders (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=see_link\">",
"       \"Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Health consequences associated with IPV are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=see_link&amp;anchor=H86601753#H86601753\">",
"     \"Intimate partner violence: Epidemiology and health consequences\", section on 'Health effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920164\">",
"    <span class=\"h2\">",
"     Concerning physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination can present clues that abuse may be present.",
"   </p>",
"   <p>",
"    The presence and location of injuries are important. Any injury without a good explanation, particularly involving the head and neck, teeth, or genital area, should raise suspicion. Typically, the victim of domestic violence sustains injuries on the central part of the body such as the breasts, abdomen, and genitals. Wounds on the head and neck, particularly neck bruising, may arise from attempted strangulation (",
"    <a class=\"graphic graphic_picture graphicRef86280 \" href=\"UTD.htm?43/30/44527\">",
"     picture 1",
"    </a>",
"    ). Wounds on the forearms often occur when a victim is in a defensive position. Bruises of different ages may be due to repeated abuse.",
"   </p>",
"   <p>",
"    There may be evidence of sexually transmitted diseases (including HIV infection) or unintended pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920180\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment for IPV in patients who present with complaints or findings that suggest underlying abuse is considered diagnosis. This is to be distinguished from screening, which involves questioning all patients who are seen for care, regardless of whether they present with a history or examination that raises concerns about possible abuse.",
"   </p>",
"   <p>",
"    Routinely asking about intimate partner violence significantly increases its detection in certain clinical situations (",
"    <a class=\"graphic graphic_table graphicRef53373 \" href=\"UTD.htm?0/48/779\">",
"     table 1",
"    </a>",
"    ). In one study, for example, 5.6 percent of 359 female trauma victims were identified as having injuries due to IPV before institution of a screening protocol in the emergency department, compared with 30 percent of 412 patients following use of the protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920187\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;The setting in which questioning occurs is important. The clinician must assure that the patient feels safe and comfortable. Clinicians should not display hesitancy, judgment, or discomfort, and should avoid using the phrases &ldquo;domestic violence&rdquo; or &ldquo;victim&rdquo; but rather they should ask about being hurt or experiencing violence.",
"   </p>",
"   <p>",
"    Patients are more likely to disclose their experience of violence when [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Providers are ready to listen and use open ended questioning.",
"     </li>",
"     <li>",
"      Questioning is done in privacy. Others present should be asked to leave for the interview and examination. Resistance to leave may be important diagnostic information.",
"     </li>",
"     <li>",
"      Providers assure confidentiality, unless someone is in grave danger, when reporting may be necessary. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=see_link&amp;anchor=H24185134#H24185134\">",
"       \"Intimate partner violence: Intervention and patient management\", section on 'Mandatory reporting'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One or only a few questions are posed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relational aspect of the questioning (eg, concern, eye contact), rather than the particular words used, may be the most important factor in assisting patients with disclosure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920194\">",
"    <span class=\"h2\">",
"     Patient expectations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of qualitative studies identified the following expectations of women in regard to assessment for IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Healthcare professionals who are nonjudgmental and compassionate",
"     </li>",
"     <li>",
"      Assurance of confidentiality",
"     </li>",
"     <li>",
"      Recognition of the complexities of violence and the difficulty of a quick resolution",
"     </li>",
"     <li>",
"      Avoidance of &ldquo;medicalizing&rdquo; the issue",
"     </li>",
"     <li>",
"      Discussion that is not rushed or hurried",
"     </li>",
"     <li>",
"      Confirmation that the violence is undeserved",
"     </li>",
"     <li>",
"      Supportive listening and feedback to bolster the patient&rsquo;s confidence",
"     </li>",
"     <li>",
"      Ability to progress at their own pace",
"     </li>",
"     <li>",
"      No pressure to disclose, leave the relationship, or press charges",
"     </li>",
"     <li>",
"      Shared decision-making and respect for the patient's decisions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another study found that women prefer a patient-centered interview format in which the clinician follows up on the patient's own cues, rather than a structured interview following tool-driven checklists [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/11\">",
"     11",
"    </a>",
"    ]. One qualitative study found that women did not want to be counseled in a directive way to leave their relationship, go to a shelter, or be told they would be reported to the police [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/12\">",
"     12",
"    </a>",
"    ]. They wished to be acknowledged and supported in their autonomy, the complexity of their life situations, and evaluated for where they were in stages of change.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3244688\">",
"    <span class=\"h2\">",
"     Caveats",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to avoid frightening, intimidating, or shaming a patient. Patients who have been involved with IPV are likely to be extremely vulnerable and may misinterpret the provider&rsquo;s best intentions. The Massachusetts Medical Society has proposed the following caveats [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid using terms like &ldquo;victim,&rdquo; &ldquo;abused,&rdquo; or &ldquo;battered&rdquo; &ndash; instead, mirror the patient&rsquo;s own word choices or use words like &ldquo;hurt,&rdquo; &ldquo;frightened,&rdquo; or &ldquo;treated badly.&rdquo;",
"     </li>",
"     <li>",
"      Do not inquire about abuse in the presence of the partner, friends, or family members.",
"     </li>",
"     <li>",
"      Do not disclose or discuss your concerns with the patient&rsquo;s partner.",
"     </li>",
"     <li>",
"      Do not ask the patient what he or she did to bring on the abuse.",
"     </li>",
"     <li>",
"      Do not ask why the patient has not left the partner, or why they may have returned to the batterer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620205\">",
"    <span class=\"h2\">",
"     Patient denial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abused patients may deny the abuse for several reasons. They may not be emotionally ready to admit the reality of the situation; they may blame themselves, or feel like a failure if they admit to being abused. They may fear rejection by the clinician, be ashamed, believe that the abuse will not happen again, fear reprisal by the abuser, believe that they have no alternatives, or they may lack knowledge of resources that could help. There may be language or cultural barriers between clinicians and patients that interfere with communication, and discomfort with using an interpreter to discuss sensitive issues.",
"   </p>",
"   <p>",
"    Patients for whom IPV is suspected but not acknowledged should be asked again at subsequent visits. There are some data to suggest that patients are more likely to disclose information after they have been asked about violence repeatedly in the healthcare setting, thereby normalizing inquiry [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920202\">",
"    <span class=\"h1\">",
"     TOOLS FOR DIAGNOSIS AND SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many tools have been proposed to detect or screen for IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/16\">",
"     16",
"    </a>",
"    ]. There is no 'gold standard' available, analogous to a biopsy, to determine the true sensitivity or specificity of these tools. There are also no studies available that address the issue of false-positive results (women reporting abuse that has not occurred).",
"   </p>",
"   <p>",
"    Lengthier tools, ideal for nuanced research, may be impractical in a busy clinic setting. Two instruments suitable for clinical, rather than research use, are The Abuse Assessment Screen (AAS) that assesses abuse in the last year including in pregnancy, and the Ongoing Abuse Screen that assesses current abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/17\">",
"     17",
"    </a>",
"    ]. The Partner Violence Scale (PVS) is shorter but takes a narrower view, assessing physical violence and safety. A meta-analysis of studies of these tools found that none were clearly superior for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4532982\">",
"    <span class=\"h2\">",
"     Framing the inquiry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before questioning a patient about abuse, it can be helpful to &ldquo;normalize&rdquo; the inquiry and frame the questioning as a routine part of everyday practice. Sample framing statements include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Violence can be a problem in many people&rsquo;s lives, so I now ask every patient about trauma or abuse they may have experienced in a relationship.",
"     </li>",
"     <li>",
"      Many patients I see are coping with an abusive relationship, so I&rsquo;ve started asking about intimate partner violence routinely.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such statements may then be followed with specific questions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920209\">",
"    <span class=\"h2\">",
"     Short surveys for practicing clinicians",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several variations of short questions have been developed for use in the course of a patient visit. A systematic review found the following tools to have high sensitivity and specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HITS (Hurt, Insult, Threaten, Scream) (English and Spanish versions)",
"     </li>",
"     <li>",
"      STaT (Slapped, Threatened, and Throw)",
"     </li>",
"     <li>",
"      HARK (Humiliation, Afraid, Rape, Kick)",
"     </li>",
"     <li>",
"      CTQ-SF (Modified Childhood Trauma Questionnaire&ndash;Short Form)",
"     </li>",
"     <li>",
"      WAST (Woman Abuse Screen Tool)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Samples of short questions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       SAFE",
"      </strong>",
"      questions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/19\">",
"       19",
"      </a>",
"      ] :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        S",
"       </strong>",
"       tress/Safety",
"      </span>",
"      - Do you feel safe in your relationship?",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        A",
"       </strong>",
"       fraid/Abused",
"      </span>",
"      - Have you ever been in a relationship where you were threatened, hurt, or afraid?",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        F",
"       </strong>",
"       riend/Family",
"      </span>",
"      - Are your friends aware you have been hurt?",
"     </li>",
"     <li>",
"      <strong>",
"       E",
"      </strong>",
"      mergency Plan - Do you have a safe place to go and the resources you need in an emergency?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The",
"      <strong>",
"       Massachusetts Medical Society",
"      </strong>",
"      Committee on Violence advises that a single question, asked routinely and without judgment, can increase the detection rate of IPV in office practice [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/20\">",
"       20",
"      </a>",
"      ]. The following questions are suggested as options, to be adapted for individual practices:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"At any time, has a partner hit, kicked, or otherwise hurt or threatened you?\"",
"     </li>",
"     <li>",
"      &ldquo;Has your partner or a former partner every hit or hurt you? Has he or she ever threatened to hurt you?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you ever feel afraid of your partner?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Do you feel safe in your relationship?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Every couple has conflicts. What happens when you and your partner have a disagreement? Do conflicts ever turn into physical fights or make you afraid for your safety?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;I see patients in my practice who have been hurt or threatened by someone they love. Is this happening to you?&rdquo;",
"     </li>",
"     <li>",
"      &ldquo;Has anyone ever hurt you emotionally, physically, or sexually?&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Abuse Assessment Screen &mdash;",
"      </strong>",
"      The three-question Abuse Assessment Screen was found to be as sensitive as more extensive questionnaires in identifying physical or sexual abuse in pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/21\">",
"       21",
"      </a>",
"      ]. The questions are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      \"Within the last year, have you been hit, slapped, kicked, or otherwise physically hurt by someone?\"",
"     </li>",
"     <li>",
"      \"Since you've been pregnant, have you been hit, slapped, kicked, or otherwise physically hurt by someone?\"",
"     </li>",
"     <li>",
"      \"Within the last year, has anyone forced you to have sexual activities?\"",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1620136\">",
"    <span class=\"h2\">",
"     Computer-based screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence suggests that patients may be more likely to reveal IPV when questionnaires are self-administered. Randomized trials have evaluated use of a computer-based tool in a variety of settings and patient populations: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an academic hospital-based family practice clinic, computer-based screening increased the detection of IPV, compared to usual care for the control population, and computer screening was acceptable to patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computer-based tools led to increased rates of disclosure of IPV, compared to usual care, in emergency department settings [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/23,24\">",
"       23,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prenatal clinic, women were screened by a combination of computerized questionnaire and a semi-structured interview [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/25\">",
"       25",
"      </a>",
"      ]. Of women who disclosed IPV (36 percent of the cohort), two-thirds disclosed in both formats, but one-third disclosed in only one of the two methods for screening; women who returned for follow-up interviews recommended that screening take place using both methods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study found that a discussion of possible IPV was initiated in only 48 percent of encounters where the computer prompted need for such evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/24\">",
"     24",
"    </a>",
"    ]. However, this is not dissimilar to rates of discussion between providers and patients following positive screens with verbal inquiry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920223\">",
"    <span class=\"h1\">",
"     GENERAL POPULATION SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no question that IPV is widely prevalent, that IPV survivors are frequently seen by healthcare providers, and that abuse leads to health problems that can be longstanding. Studies have found that routine screening increases the detection of intimate partner violence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Data are less robust that screening for IPV improves health outcomes for the abused or perpetrator [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, given the lack of harm from screening, we suggest routine screening for intimate partner violence for all patients on initial visits to primary care clinicians, obstetrician-gynecologists, to the emergency department, and on hospital admission.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534239\">",
"    <span class=\"h2\">",
"     Benefits and harms of screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence for the impact of screening for IPV on patient outcomes is limited by methodologic and ethical challenges. These include the inability to withhold intervention from control group participants identified with IPV, reliance on self-reported measures, lack of a reference standard, a high loss to follow-up among this patient population, and inability to conduct a double-blind trial. Given these limitations, several trials to date best address these issues, though they are limited by studying only two populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of women (primarily African American, high school education or less, and uninsured) assigned participants being seen in primary healthcare centers to one of three groups: computerized screening plus a resource list for positive screens, resource list only, or usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/30\">",
"       30",
"      </a>",
"      ]. At one-year follow-up, there was no significant difference between groups in quality of life, healthcare utilization, absence from work, or recurrence of partner violence. Thus, one-time screening and limited intervention with provision of a resource list did not improve outcomes related to IPV for this population.",
"     </li>",
"     <li>",
"      A cluster randomized trial of screening for IPV involved women aged 18 to 64 years presenting for care at clinics providing either primary care, acute care, or gynecologic services in Canada [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/28\">",
"       28",
"      </a>",
"      ]. Clinicians in all clinics received training in responding to disclosure of IPV. Patients assigned to the screening group completed the WAST questionnaire before their visit, and clinicians were told of positive scores. Patients in the non-screening group completed the WAST questionnaire after their visit and both groups also completed a 30-item Composite Abuse Scale after the visit. The prevalence of abuse at the initial visit was 13 and 12 percent for screened and nonscreened groups. Clinicians discussed IPV with patients at the initial visit of 44 percent of screened women and 8 percent of nonscreened women. Abused women in both groups were referred for follow-up care. At 18 month follow-up, the incidence of IPV, posttraumatic stress disorder, and alcohol abuse was decreased in both groups and both groups showed improvement in scores of depression and quality of life; there was no difference in outcomes between the groups. Loss to follow-up was greater than 40 percent in both groups, and women at higher risk for abuse were most likely to be lost to follow-up. No harm was found from screening. Thus, clinician intervention did not impact outcomes in the randomized trial, but screening (which took place for both groups) was associated with improved outcomes in what was essentially an observational study.",
"     </li>",
"     <li>",
"      A randomized trial compared perinatal counseling to usual care in 1044 pregnant African American women in Washington, DC, one-third of whom screened positive at baseline for IPV by a computer risk-assessment tool [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/31\">",
"       31",
"      </a>",
"      ]. The intervention group met with trained social workers who provided integrated counseling in two to eight sessions addressing smoking cessation, depression, and IPV-related danger assessment and information on safety and community resources. Retention was high (91 percent) and women in the intervention group had decreased rates of recurrent IPV (OR 0.48, 95% CI 0.29-0.80) as well as better birth outcomes and decreased rates of depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No adverse effects of screening and intervention for IPV were identified in two of three trials reporting adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/28,32\">",
"     28,32",
"    </a>",
"    ]; one trial involving home visitation for at-risk new mothers suggested an increase in verbal abuse for women randomly assigned to the intervention, although the difference was not statistically significant compared to women in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 20 percent of women patients in surveys of general practices in London and Ireland objected to screening for domestic violence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/27\">",
"     27",
"    </a>",
"    ]. Discomfort with screening was greatest among women who experienced physical or sexual violence related to IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/34\">",
"     34",
"    </a>",
"    ]. Concerns raised by survey respondents included loss of privacy, worries about provoking abuse with disclosure, emotional distress, fear of judgment by the provider, and disappointment in the provider&rsquo;s response. This highlights the fear and sensitivity of victims of abuse and the need for assuring safety and support with screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920230\">",
"    <span class=\"h2\">",
"     Recommendations by various groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Groups making recommendations suggest that physicians be more alert to the possibility of IPV, particularly in specific clinical situations (",
"    <a class=\"graphic graphic_table graphicRef53373 \" href=\"UTD.htm?0/48/779\">",
"     table 1",
"    </a>",
"    ). Many groups suggest screening all women for IPV, regardless of the setting. The frequency of screening has not been addressed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The US Preventive Services Task Force (USPSTF) issued revised recommendations for screening for IPV in 2013 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. The guideline recommends that clinicians screen women of childbearing age (14 to 46 years old) for IPV, and provide or refer women to intervention services when appropriate. The guideline is based on a systematic review published in June 2012 on behalf of the USPSTF that found that several instruments detect IPV at a high rate and that screening is associated with minimal harms and many potential benefits [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/2\">",
"       2",
"      </a>",
"      ]. In a 2004 guideline, citing lack of proven effectiveness for screening instruments and lack of evidence that screening improves clinical outcomes, the USPSTF concluded that there was insufficient evidence to support screening for IPV in asymptomatic populations [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/37\">",
"       37",
"      </a>",
"      ]. This generated much controversy and dispute about the importance of the outcomes that were evaluated.",
"     </li>",
"     <li>",
"      The American College of Obstetricians and Gynecologists (ACOG) revised previous recommendations in 2012, advising that all women be screened for IPV at periodic intervals, including during obstetric care (at the first prenatal visit, at least once per trimester, at the post partum checkup) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/38\">",
"       38",
"      </a>",
"      ]. Physicians should offer ongoing support and review available prevention and referral options.",
"     </li>",
"     <li>",
"      The Institute of Medicine, as of July 2011, recommends that all women and girls be screened for IPV, due to the magnitude of potential IPV harms [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Joint Commission on Accreditation of Healthcare Organizations recommends that hospitals use criteria to identify possible victims of abuse and neglect upon hospital entry and on an ongoing basis, educate staff about how to recognize signs of abuse, assist with referrals of possible victims, and report abuse in accordance with law and regulation. They include domestic abuse in their list of abuse conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Medical Association (AMA) recommends that all patients be routinely screened for IPV, with inquiry about any history of family violence [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/41\">",
"       41",
"      </a>",
"      ]. Safety should be assessed when IPV is identified, before the patient leaves the office, appropriate referrals made, and physicians should be aware of local resources. They also recommend that physicians become involved in appropriate local programs designed to prevent violence and its effects at the community level.",
"     </li>",
"     <li>",
"      The Canadian Task Force on Preventive Health Care found insufficient evidence (in 2003) to recommend for or against routine universal screening for violence against either pregnant or nonpregnant women, but recommends that clinicians be alert to signs and symptoms of abuse [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/42\">",
"       42",
"      </a>",
"      ]. The Task Force found fair evidence that women who have spent at least one night in a shelter should be referred to a structured program of advocacy services, and it found conflicting evidence regarding batterer interventions (with or without partner participation).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920246\">",
"    <span class=\"h2\">",
"     Screening implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both providers and patients have expressed discomfort with screening for IPV. Though many national groups have recommended screening, rates of screening in primary care settings have been low (less than 13 percent in one internal medicine clinic) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Barriers for clinicians to screen for IPV have been identified and categorized in five areas in one systematic review: personal barriers, resource barriers, perceptions and attitudes, fears, and patient-related barriers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/44\">",
"     44",
"    </a>",
"    ]. The most frequent barriers were personal discomfort, lack of knowledge, and time constraints. Other issues underlying clinician reluctance to integrate routine screening into practice include uncertainty regarding how to help if IPV is identified, privacy, legal, and personal safety concerns. One study noted more discomfort among male clinicians, and those in private practice, with less discomfort for gynecologists, hospital-based practices, and providers who have been in practice for 5 to 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systems model approach can improve screening uptake and patient referral for services [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. This may involve staff training including medical and mental health clinicians as well as social workers, providing materials for distribution to female patients, implementing computer-based or other self-administered screening tools, alerts or prompts on patient charts for providers to inquire about IPV and follow-up when IPV is identified, identifying community resources for referral and working with community advocates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920267\">",
"    <span class=\"h2\">",
"     Synthesis of screening recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying patients who are exposed to violence provides clinicians with insight in order to appropriately address medical problems that may be sequelae of violence and to intervene to prevent bodily harm. Educating patients about violence by making it a part of the medical conversation may make it more likely for reticent patients to disclose at a subsequent visit. It also sends a message about prevention to victims and perpetrators, by heightening awareness that providers feel this behavior is wrong and that they are willing and able to assist.",
"   </p>",
"   <p>",
"    All people who present with clinical symptoms or signs listed in the table should be asked about IPV (",
"    <a class=\"graphic graphic_table graphicRef53373 \" href=\"UTD.htm?0/48/779\">",
"     table 1",
"    </a>",
"    ). In addition, we suggest that all patients should routinely be screened for IPV on initial visits to primary care clinicians, obstetrician-gynecologists, and medical subspecialists (particularly gastroenterologists and neurologists). Any injury should trigger inquiry about the situation that engendered it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=see_link&amp;anchor=H24185091#H24185091\">",
"     \"Intimate partner violence: Intervention and patient management\", section on 'Intervention, counseling, and referral'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any of the short questions discussed above would be appropriate for screening. (See",
"    <a class=\"local\" href=\"#H8920209\">",
"     'Short surveys for practicing clinicians'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8920326\">",
"    <span class=\"h1\">",
"     DETECTING PERPETRATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detecting perpetrators and working towards IPV prevention is an important goal, but it is uncertain how best to detect and treat perpetrators of violence. Providers have been skeptical about detecting a problem for which they cannot offer helpful assistance and may grapple with their own discomfort when caring for these patients.",
"   </p>",
"   <p>",
"    Many perpetrators also have been victims, further complicating a sensitive issue. Childhood adversity and adult stressors are causal for both perpetration of abuse and victimization in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies note an association with substance use, particularly alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/50-55\">",
"     50-55",
"    </a>",
"    ], and suggest that providers inquire if the patient has done things while under the influence that they subsequently regret. A longitudinal study in New Zealand suggests that alcohol may be causal in 4 to 9 percent of IPV events [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/53\">",
"     53",
"    </a>",
"    ]. One survey suggested that problem drinking in perpetrators was associated with an eightfold increase in IPV [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/55\">",
"     55",
"    </a>",
"    ]. Many, but not all, studies have been done in male college students, raising some question of generalizability. If a woman is drinking excessively she may be more at risk for both perpetration and victimization relationships [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study found that use of alcohol and cocaine, both independently and together, was associated with IPV perpetration, whereas cannabis and opioid use disorders were correlated with victimization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6393/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4534962\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Victims of intimate partner violence (IPV) are found among people of all ages, socioeconomic classes, ethnicities, gender identities, and sexual preferences. While not all patients experiencing IPV exhibit any signs or symptoms, certain features should heighten suspicion of IPV. These include inconsistent explanation of injuries, delay in seeking treatment or missed appointments, frequent emergency department visits, late prenatal care, inappropriate affect, overly attentive partners, and reluctance to be examined. Intimate partner violence is associated with a perception of overall poor health with somatic (often gynecologic) and psychologic impact. (See",
"      <a class=\"local\" href=\"#H8920150\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routinely asking about intimate partner violence significantly increases its detection in certain clinical situations (",
"      <a class=\"graphic graphic_table graphicRef53373 \" href=\"UTD.htm?0/48/779\">",
"       table 1",
"      </a>",
"      ). In questioning a patient in whom IPV is suspected, providers should be cognizant of patient&rsquo;s expectations for nonjudgmental, compassionate listening that allows the patient to progress at his or her own pace, with shared decision-making, respect for the patient&rsquo;s decisions, and no pressure to disclose, leave the relationship, or press charges. Terms like &ldquo;victim,&rdquo; &ldquo;domestic violence,&rdquo; &ldquo;abused,&rdquo; or &ldquo;battered&rdquo; should be avoided. (See",
"      <a class=\"local\" href=\"#H8920194\">",
"       'Patient expectations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abused patients may deny the abuse for multiple reasons. Patients for whom IPV is suspected but not acknowledged should be asked again at subsequent visits. (See",
"      <a class=\"local\" href=\"#H1620205\">",
"       'Patient denial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Before questioning a patient about abuse, it can be helpful to &ldquo;normalize&rdquo; the inquiry and frame the questioning as a routine part of everyday practice. Possible statements include &ldquo;Violence can be a problem in many people&rsquo;s lives, so I now ask every patient about trauma or abuse they may have experienced in a relationship&rdquo; or &ldquo;Many patients I see are coping with an abusive relationship, so I&rsquo;ve started asking about intimate partner violence routinely.&rdquo; (See",
"      <a class=\"local\" href=\"#H4532982\">",
"       'Framing the inquiry'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several short tools have been developed for use in screening for IPV. Single questions may be sufficient for screening. Self-administered questionnaires, including computer-based assessment tools, may be more effective that face-to-face questioning. (See",
"      <a class=\"local\" href=\"#H8920209\">",
"       'Short surveys for practicing clinicians'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1620136\">",
"       'Computer-based screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Methodologic problems intrinsic to studies of IPV make it difficult to design a randomized trial to determine the effectiveness of screening on patient outcomes. Screening does not appear to cause harm and observational studies suggest that interventions for victims of IPV identified through screening can decrease rates of IPV and improve health outcomes, including birth outcomes in pregnant women. (See",
"      <a class=\"local\" href=\"#H4534239\">",
"       'Benefits and harms of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple professional organizations endorse screening for IPV, but differ in suggested target populations and do not address screening frequency. We suggest routine screening for intimate partner violence for all patients on initial visits to primary care clinicians, obstetrician-gynecologists, to the emergency department, and on hospital admission (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Screening by other medical specialists, including gastroenterologists or neurologists, would also be appropriate. Additionally, any patient presenting with clinical symptoms or signs suggesting possible IPV should be asked about IPV (",
"      <a class=\"graphic graphic_table graphicRef53373 \" href=\"UTD.htm?0/48/779\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tjaden P, Thoennes N. Extent, nature, and consequences of intimate partner violence: findings from the National Violence Against Women Survey. Publication No. NCJ-181867, US Department of Justice, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/2\">",
"      Nelson HD, Bougatsos C, Blazina I. Screening women for intimate partner violence: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 2012; 156:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Adverse health conditions and health risk behaviors associated with intimate partner violence--United States, 2005. MMWR Morb Mortal Wkly Rep 2008; 57:113.",
"     </a>",
"    </li>",
"    <li>",
"     World Heatlh Organization. Violence by intimate partners. Available at: file://www.who.int/violence_injury_prevention/violence/global_campaign/en/chap4.pdf (Accessed on April 20, 2010).",
"    </li>",
"    <li>",
"     Intimate Partner Violence in  Practical Gynecology: A Guide for the Primary Care Physician, 2nd ed, Ryden J, Blumenthal PD, Charney P (Eds), American College of Physicans, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/6\">",
"      McCloskey LA, Williams CM, Lichter E, et al. Abused women disclose partner interference with health care: an unrecognized form of battering. J Gen Intern Med 2007; 22:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/7\">",
"      Ellsberg M, Jansen HA, Heise L, et al. Intimate partner violence and women's physical and mental health in the WHO multi-country study on women's health and domestic violence: an observational study. Lancet 2008; 371:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/8\">",
"      McLeer SV, Anwar R. A study of battered women presenting in an emergency department. Am J Public Health 1989; 79:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/9\">",
"      Taket A, Nurse J, Smith K, et al. Routinely asking women about domestic violence in health settings. BMJ 2003; 327:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/10\">",
"      Justo D. Methadone-induced long QT syndrome vs methadone-induced torsades de pointes. Arch Intern Med 2006; 166:2288; author reply 2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/11\">",
"      McCord-Duncan EC, Floyd M, Kemp EC, et al. Detecting potential intimate partner violence: which approach do women want? Fam Med 2006; 38:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/12\">",
"      Chang JC, Cluss PA, Ranieri L, et al. Health care interventions for intimate partner violence: what women want. Womens Health Issues 2005; 15:21.",
"     </a>",
"    </li>",
"    <li>",
"     Intimate Partner Violence. Masachusetts Medical Society Committee on Violence Intervention and Prevention. 5th Edition. file://www.massmed.org/AM/Template.cfm?Section=Home6&amp;CONTENTID=36015&amp;TEMPLATE=/CM/ContentDisplay.cfm (Accessed on August 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/14\">",
"      Rodriguez MA, Quiroga SS, Bauer HM. Breaking the silence. Battered women's perspectives on medical care. Arch Fam Med 1996; 5:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/15\">",
"      Rodriguez MA, Bauer HM, Flores-Ortiz Y, Szkupinski-Quiroga S. Factors affecting patient-physician communication for abused Latina and Asian immigrant women. J Fam Pract 1998; 47:309.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control. Intimate partner violence and sexual violence victimization assessment instruments for use in healthcare settings. Available at: file://www.cdc.gov/ncipc/dvp/IPV/IPVandSV-Screening.pdf (Accessed on April 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/17\">",
"      Ernst AA, Weiss SJ, Cham E, Marquez M. Comparison of three instruments for assessing ongoing intimate partner violence. Med Sci Monit 2002; 8:CR197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/18\">",
"      Rabin RF, Jennings JM, Campbell JC, Bair-Merritt MH. Intimate partner violence screening tools: a systematic review. Am J Prev Med 2009; 36:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/19\">",
"      Ashur ML. Asking about domestic violence: SAFE questions. JAMA 1993; 269:2367.",
"     </a>",
"    </li>",
"    <li>",
"     Alpert, EJ. Intimate Partner Violence. The clinician's guide to identification, assessment, intervention, and prevention. 5th Edition. Massachusetts Medical Society, 2010. file://www.massmed.org/AM/Template.cfm?Section=Home6&amp;CONTENTID=36015&amp;TEMPLATE=/CM/ContentDisplay.cfm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/21\">",
"      McFarlane J, Parker B, Soeken K, Bullock L. Assessing for abuse during pregnancy. Severity and frequency of injuries and associated entry into prenatal care. JAMA 1992; 267:3176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/22\">",
"      Ahmad F, Hogg-Johnson S, Stewart DE, et al. Computer-assisted screening for intimate partner violence and control: a randomized trial. Ann Intern Med 2009; 151:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/23\">",
"      Rhodes KV, Lauderdale DS, He T, et al. \"Between me and the computer\": increased detection of intimate partner violence using a computer questionnaire. Ann Emerg Med 2002; 40:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/24\">",
"      Rhodes KV, Drum M, Anliker E, et al. Lowering the threshold for discussions of domestic violence: a randomized controlled trial of computer screening. Arch Intern Med 2006; 166:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/25\">",
"      Chang JC, Dado D, Schussler S, et al. In person versus computer screening for intimate partner violence among pregnant patients. Patient Educ Couns 2012; 88:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/26\">",
"      Freund KM, Bak SM, Blackhall L. Identifying domestic violence in primary care practice. J Gen Intern Med 1996; 11:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/27\">",
"      Ramsay J, Richardson J, Carter YH, et al. Should health professionals screen women for domestic violence? Systematic review. BMJ 2002; 325:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/28\">",
"      MacMillan HL, Wathen CN, Jamieson E, et al. Screening for intimate partner violence in health care settings: a randomized trial. JAMA 2009; 302:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/29\">",
"      Wathen CN, MacMillan HL. Interventions for violence against women: scientific review. JAMA 2003; 289:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/30\">",
"      Klevens J, Kee R, Trick W, et al. Effect of screening for partner violence on women's quality of life: a randomized controlled trial. JAMA 2012; 308:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/31\">",
"      Kiely M, El-Mohandes AA, El-Khorazaty MN, et al. An integrated intervention to reduce intimate partner violence in pregnancy: a randomized controlled trial. Obstet Gynecol 2010; 115:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/32\">",
"      McFarlane JM, Groff JY, O'Brien JA, Watson K. Secondary prevention of intimate partner violence: a randomized controlled trial. Nurs Res 2006; 55:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/33\">",
"      Bair-Merritt MH, Jennings JM, Chen R, et al. Reducing maternal intimate partner violence after the birth of a child: a randomized controlled trial of the Hawaii Healthy Start Home Visitation Program. Arch Pediatr Adolesc Med 2010; 164:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/34\">",
"      Zeitler MS, Paine AD, Breitbart V, et al. Attitudes about intimate partner violence screening among an ethnically diverse sample of young women. J Adolesc Health 2006; 39:119.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/35\">",
"      Moyer VA, U.S. Preventive Services Task Force*. Screening for intimate partner violence and abuse of elderly and vulnerable adults: u.s. Preventive services task force recommendation statement. Ann Intern Med 2013; 158:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/36\">",
"      Screening for Intimate Partner Violence and Abuse of Vulnerable Adults: U.S. Preventive Services Task Force Recommendation. Ann Intern Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/37\">",
"      U.S. Preventive Services Task Force. Screening for family and intimate partner violence: recommendation statement. Ann Fam Med 2004; 2:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/38\">",
"      ACOG Committee Opinion No. 518: Intimate partner violence. Obstet Gynecol 2012; 119:412.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Clinical Preventive Services for Women: Closing the Gaps. July 2011. Available at: file://iom.edu/Reports/2011/Clinical-Preventive-Services-for-Women-Closing-the-Gaps.aspx (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     Joint Commission on Accreditation of Healthcare Organizations. Accreditation manual for hospitals, Joint Commission on Accrediation of Healthcare Organizations, Oakbrook Terrace, IL 2009.",
"    </li>",
"    <li>",
"     American Medical Association. H-515.965 Family and Intimate Partner Violence. AMA Policy. p. 75. Available at: file://www.ama-assn.org/resources/doc/hod/i-09-policies.pdf (Accessed on June 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/42\">",
"      Wathen CN, MacMillan HL, Canadian Task Force on Preventive Health Care. Prevention of violence against women: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2003; 169:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/43\">",
"      Rodriguez MA, Bauer HM, McLoughlin E, Grumbach K. Screening and intervention for intimate partner abuse: practices and attitudes of primary care physicians. JAMA 1999; 282:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/44\">",
"      Sprague S, Madden K, Simunovic N, et al. Barriers to screening for intimate partner violence. Women Health 2012; 52:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/45\">",
"      Jaffee KD, Epling JW, Grant W, et al. Physician-identified barriers to intimate partner violence screening. J Womens Health (Larchmt) 2005; 14:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/46\">",
"      McCaw B, Berman WH, Syme SL, Hunkeler EF. Beyond screening for domestic violence: a systems model approach in a managed care setting. Am J Prev Med 2001; 21:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/47\">",
"      Feder G, Davies RA, Baird K, et al. Identification and Referral to Improve Safety (IRIS) of women experiencing domestic violence with a primary care training and support programme: a cluster randomised controlled trial. Lancet 2011; 378:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/48\">",
"      Roberts AL, McLaughlin KA, Conron KJ, Koenen KC. Adulthood stressors, history of childhood adversity, and risk of perpetration of intimate partner violence. Am J Prev Med 2011; 40:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/49\">",
"      Roberts AL, Gilman SE, Fitzmaurice G, et al. Witness of intimate partner violence in childhood and perpetration of intimate partner violence in adulthood. Epidemiology 2010; 21:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/50\">",
"      Fossos N, Neighbors C, Kaysen D, Hove MC. Intimate partner violence perpetration and problem drinking among college students: The roles of expectancies and subjective evaluations of alcohol aggression. J Stud Alcohol Drugs 2007; 68:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/51\">",
"      White HR, Chen PH. Problem drinking and intimate partner violence. J Stud Alcohol 2002; 63:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/52\">",
"      Smith PH, Homish GG, Leonard KE, Cornelius JR. Intimate partner violence and specific substance use disorders: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Addict Behav 2012; 26:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/53\">",
"      Boden JM, Fergusson DM, Horwood LJ. Alcohol misuse and violent behavior: findings from a 30-year longitudinal study. Drug Alcohol Depend 2012; 122:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/54\">",
"      Coker AL, Smith PH, McKeown RE, King MJ. Frequency and correlates of intimate partner violence by type: physical, sexual, and psychological battering. Am J Public Health 2000; 90:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6393/abstract/55\">",
"      Sharps PW, Campbell J, Campbell D, et al. The role of alcohol use in intimate partner femicide. Am J Addict 2001; 10:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15294 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-61.234.146.186-2A6F391156-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6393=[""].join("\n");
var outline_f6_15_6393=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4534962\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920143\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920150\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920157\">",
"      Common presenting complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920164\">",
"      Concerning physical findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920180\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920187\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920194\">",
"      Patient expectations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3244688\">",
"      Caveats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1620205\">",
"      Patient denial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920202\">",
"      TOOLS FOR DIAGNOSIS AND SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4532982\">",
"      Framing the inquiry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920209\">",
"      Short surveys for practicing clinicians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1620136\">",
"      Computer-based screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920223\">",
"      GENERAL POPULATION SCREENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4534239\">",
"      Benefits and harms of screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920230\">",
"      Recommendations by various groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920246\">",
"      Screening implementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8920267\">",
"      Synthesis of screening recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8920326\">",
"      DETECTING PERPETRATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4534962\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/15294\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15294|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/30/44527\" title=\"picture 1\">",
"      Strangulation findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/15294|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/48/779\" title=\"table 1\">",
"      Patients to ask about violence",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/32/522?source=related_link\">",
"      Dissociative aspects of posttraumatic stress disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/41/5784?source=related_link\">",
"      Intimate partner violence: Epidemiology and health consequences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14183?source=related_link\">",
"      Intimate partner violence: Intervention and patient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44713?source=related_link\">",
"      Panic disorder: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5033?source=related_link\">",
"      Substance use disorders: Principles for recognition and assessment in general medical care",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6394="Ischemic reperfusion injury of the heart";
var content_f6_15_6394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ischemic reperfusion injury of the heart",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Duane S Pinto, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6394/contributors\">",
"     C Michael Gibson, MS, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Joanna J Wykrzykowska, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/15/6394/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/15/6394/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary reperfusion therapies, including primary percutaneous coronary intervention (PCI) and thrombolysis, are the standard of care for the treatment of acute coronary syndromes. Prompt restoration of blood flow to ischemic myocardium limits infarct size and reduces mortality. Paradoxically, however, the return of blood flow can also result in additional cardiac damage and complications, referred to as reperfusion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Such damage is more likely when reperfusion therapy is delayed.",
"   </p>",
"   <p>",
"    Effective therapies to reduce or prevent reperfusion injury have proven elusive. Despite an improved understanding of the pathophysiology of this process and encouraging preclinical trials of multiple agents, most of the clinical trials to prevent reperfusion injury have been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Despite these problems, adjunctive therapies to limit reperfusion injury remain an active area of investigation.",
"   </p>",
"   <p>",
"    This card will discuss the pathophysiology and manifestations of reperfusion injury, as well as potential therapeutic strategies. More general discussions of the clinical use of primary PCI and thrombolytic therapy in acute myocardial infarction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion injury refers to myocardial, vascular, or electrophysiological dysfunction that is induced by the restoration of blood flow to previously ischemic tissue. Manifestations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reperfusion arrhythmias",
"     </li>",
"     <li>",
"      Endothelial cell damage leading to microvascular dysfunction",
"     </li>",
"     <li>",
"      Myocardial stunning",
"     </li>",
"     <li>",
"      Myocyte death and infarction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;When blood flow to cardiac myocytes is disrupted by occlusion of a coronary artery, a series of events is set in motion that results in cellular injury and death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/6\">",
"     6",
"    </a>",
"    ]. These processes are largely related to energy production and utilization and include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced energy production with a fall in intracellular ATP levels",
"     </li>",
"     <li>",
"      A transition from aerobic to anaerobic energy utilization",
"     </li>",
"     <li>",
"      An accumulation of the products of anaerobic metabolism",
"     </li>",
"     <li>",
"      Reduced intracellular pH",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These phenomena lead to dramatic distortions in myocyte physiology and architecture, including mitochondrial and sarcolemmal injury and alterations in intracellular calcium handling. Initially, the damage is reversible, and restoration of blood flow during this period will lead to recovery of normal structures and function. However, if ischemia persists for an extended period of time, this damage becomes irreversible and cell death occurs.",
"   </p>",
"   <p>",
"    Prior to cell death there is a period during which the ischemic myocyte is viable, but vulnerable to further injury if blood flow is restored (ie, reperfusion injury). During this period, the reintroduction of oxygen and energy into an abnormal cellular environment triggers additional events that produce further myocyte damage.",
"   </p>",
"   <p>",
"    Factors that contribute to reperfusion injury include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Damage to cellular and organelle membranes, including mitochondria",
"     </li>",
"     <li>",
"      Myocyte hypercontracture",
"     </li>",
"     <li>",
"      Free radical formation",
"     </li>",
"     <li>",
"      Aggregation of leukocytes and inflammatory mediators",
"     </li>",
"     <li>",
"      Platelet activation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activation of the pro-apoptotic signaling cascade [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endothelium damage and vasoconstriction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitochondrial dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mitochondrial membrane is ordinarily impermeable to most ions and metabolites. During periods of ischemia, however, several changes alter mitochondrial membrane permeability. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elevated intra-mitochondrial calcium concentrations",
"     </li>",
"     <li>",
"      Reduced levels of adenine nucleotide concentrations",
"     </li>",
"     <li>",
"      Oxidative stress induced by ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In combination, these factors prime a non-specific pore in the inner mitochondrial membrane called the mitochondrial permeability transition pore (MPTP) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/11\">",
"     11",
"    </a>",
"    ]. At the time of reperfusion, with the restoration of blood flow and the normalization of cellular pH, this pore opens and allows proteins to move freely across the membrane, with two important consequences:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increased osmotic load induced by the flow of constituents into the mitochondrial body causes the mitochondrion to swell and ultimately forces rupture of the outer membrane. The subsequent release of mitochondrial proteins stimulates apoptosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Apoptosis'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Disruption of the ionic gradient across the mitochondrial membrane uncouples oxidative phosphorylation and results in the hydrolyzing of ATP instead of its synthesis. The subsequent fall in ATP levels further disrupts ionic and metabolic homeostasis and leads to the activation of degradative enzymes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, Poly(ADP-ribose) polymerase-1 (PARP-1) overactivation and its effect on Mitochondrial Respiratory Chain Complex I may also play a role in reperfusion injury. Excessive PARP-1 activation can impair the function of other cellular organelles, including mitochondria and accelerate production of reactive oxygen species [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/12\">",
"     12",
"    </a>",
"    ]. PARP inhibitors have been shown to reduce infarct size in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Myocyte hypercontracture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of blood flow to previously ischemic cells can result in myocyte hypercontracture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/15\">",
"     15",
"    </a>",
"    ]. Factors that contribute to hypercontracture include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intracellular calcium &mdash; During an ischemic period, intracellular calcium increases due to impaired calcium cycling and sarcolemmal damage [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/16\">",
"       16",
"      </a>",
"      ]. This process can be exacerbated with reperfusion. The restoration of a normal extracellular pH after reperfusion produces a hydrogen gradient across the cell membrane. The",
"      <span class=\"nowrap\">",
"       sodium/hydrogen",
"      </span>",
"      <span class=\"nowrap\">",
"       (Na/H)",
"      </span>",
"      exchanger is activated and causes a net influx of sodium into the cytosol. Under normal conditions, the resulting increase in intracellular sodium would be corrected by the",
"      <span class=\"nowrap\">",
"       sodium/potassium",
"      </span>",
"      <span class=\"nowrap\">",
"       (Na/K)",
"      </span>",
"      ATPase. However, this channel may not function normally after a period of ischemia due to a lack of energy and structural damage. In this setting, the sodium excess causes the",
"      <span class=\"nowrap\">",
"       sodium/calcium",
"      </span>",
"      <span class=\"nowrap\">",
"       (Na/Ca)",
"      </span>",
"      channel to run in reverse, producing an influx of calcium into the already calcium-overloaded cell.",
"     </li>",
"     <li>",
"      Reoxygenation and reenergization of the myocyte &mdash; Return of blood flow provides oxygen and energy that stimulates myofibrils, and, in the setting of increased calcium, contraction is uncontrolled and excessive.",
"     </li>",
"     <li>",
"      Restoration of normal acid-base status &mdash; Reduced cytosolic pH during ischemia inhibits myofibrillar contraction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/17\">",
"       17",
"      </a>",
"      ]. With restoration of blood flow, a normal pH is rapidly restored in the extracellular and then the intracellular space, removing the acidic inhibition to contraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mechanisms by which hypercontracture can result in additional cardiac injury include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytoskeletal elements can be significantly damaged, ultimately resulting in cell death.",
"     </li>",
"     <li>",
"      Myocytes tearing away from the tight intercellular junctions during hypercontracture can cause damage to the sarcolemma of adjacent cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxygen and other free radicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free radicals are produced within minutes of reperfusion and continue to be generated for hours after the restoration of blood flow to ischemic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/19\">",
"     19",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Superoxide anion (&bull;O2)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       Hydrogen peroxide",
"      </a>",
"      (H2O2)",
"     </li>",
"     <li>",
"      Hypochlorous acid (HOCl)",
"     </li>",
"     <li>",
"      Nitric oxide-derived peroxynitrite",
"     </li>",
"     <li>",
"      Hydroxyl radical (&bull;OH)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several mechanisms have been proposed for the development of these free radicals including xanthine oxidase, activated neutrophils, electron leakage from ischemic mitochondrion, catecholamine oxidation, as well as cyclooxygenase and lipoxygenase enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/20\">",
"     20",
"    </a>",
"    ]. The relative importance of each of these pathways is not clear, but they are probably interrelated and may potentiate one another.",
"   </p>",
"   <p>",
"    Free radicals damage myocytes directly by altering membrane proteins and phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/21\">",
"     21",
"    </a>",
"    ]. Because these membrane constituents play crucial roles as receptors, enzymes, and ion channels, free radical injury can lead to fatal metabolic and structural derangements. As an example, oxygen radicals injure the sarcolemma and may impair contractile function of the myocyte on this basis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/20\">",
"     20",
"    </a>",
"    ]. The role for free radicals as a source of significant myocardial damage is further supported by studies showing that free radical scavengers, such as superoxide dismutase, administered during thrombolytic therapy help preserve myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/22\">",
"     22",
"    </a>",
"    ]. Finally, reactive oxygen species stimulate leukocyte activation, chemotaxis, and leukocyte-endothelial adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Leukocyte aggregation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors induced by ischemia and reperfusion trigger leukocyte aggregation and activation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophils are stimulated after plasma membrane phospholipase A2 is activated to form arachidonic acid, which is an important precursor in the inflammation pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cytokines and complement are released from damaged myocardium [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/23-25\">",
"       23-25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      New expression of adhesion molecules, diminished release of nitric oxide (NO), and changes in the actin cytoskeleton allow greater vascular permeability, giving neutrophils access to vulnerable myocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neutrophil accumulation in non-perfused microvessels may contribute to the \"no-reflow\" phenomenon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/27\">",
"     27",
"    </a>",
"    ]. Once in the extravascular space, leukocytes can release proteases and elastases that destroy the cell membrane and cause cell death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, the roles of the various inflammatory mediators are complex and incompletely understood. Although they play a role in reperfusion injury, some also appear to have cardioprotective effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Platelet activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Circulating platelets become activated early during reperfusion, and their degree of activation is related to the duration of preceding ischemia. Furthermore, the degree of platelet activation was related to the extent of reperfusion injury. These observations support the possibility of an important role for activated platelets in reperfusion injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Complement activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complement activation appears to play a role in the \"no-reflow\" phenomenon and possibly reperfusion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/8\">",
"     8",
"    </a>",
"    ]. Terminal complement cascade species directly injure the endothelium, rendering it incapable of elaborating vasodilatory compounds such as NO. This perpetuates a cycle of vasoconstriction and reduction in microvascular perfusion leading to apoptosis not only within the infarct area, but also in the border zone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Apoptosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apoptosis, or programmed cell death, has a number of features that distinguish it from necrosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Apoptosis can occur in response limited molecular damage that is otherwise not sufficient to cause a fatal loss of cellular integrity.",
"     </li>",
"     <li>",
"      Apoptosis is an energy-dependent process.",
"     </li>",
"     <li>",
"      Apoptosis is an organized sequence of events triggered by specific signals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While ischemic damage occurs principally through necrosis, reperfusion injury may also act through apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In a rabbit model, markers of apoptosis found in reperfused tissue were not present in normal tissue or tissue injured solely by ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/31\">",
"     31",
"    </a>",
"    ]. Others have reported the appearance of apoptotic cells in the peri-necrotic zone during reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/33\">",
"     33",
"    </a>",
"    ] and suggested that understanding the different contributions of necrosis and apoptosis to reperfusion injury may help identify novel treatment strategies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A link between reperfusion and apoptosis is supported by studies demonstrating the role of magnesium-dependent superoxide dismutase and oxygen radical formation in the activation of pro-apoptotic factors. An apoptosis repressor is capable of inhibiting this process and reducing the extent of myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of ischemic reperfusion injury include arrhythmias, microvascular dysfunction, myocardial stunning, and myocyte death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reperfusion arrhythmias are common in patients treated with thrombolytic therapy, primary PCI, and cardiac surgery. The arrhythmia that is most commonly associated with reperfusion is an accelerated idioventricular rhythm (AIVR). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\", section on 'Reperfusion arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reperfusion arrhythmias may be mediated by mitochondrial dysfunction. Following prolonged ischemia, the mitochondrion may not be able to restore or maintain its inner membrane potential, thereby destabilizing the action potential and increasing susceptibility to arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mitochondrial dysfunction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ventricular tachycardia and ventricular fibrillation can also occur after thrombolytic therapy, however these arrhythmias are more likely to reflect persistent occlusion and infarction than a reperfused infarct-related artery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/38\">",
"     38",
"    </a>",
"    ]. The pathogenesis of reperfusion arrhythmias is discussed extensively elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=see_link\">",
"     \"Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Microvascular dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preservation of the coronary microvasculature is essential to the ultimate recovery of myocardial function [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/39\">",
"     39",
"    </a>",
"    ]. Microvascular dysfunction, or the \"no reflow\" phenomenon, refers to the impairment of resting blood flow within the post-ischemic vasculature. The clinical significance of microvascular dysfunction lies in its association with worse cardiovascular outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Features associated with reperfusion injury that may contribute to microvascular dysfunction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet activation, which has been shown to contribute to microvascular injury and reperfusion injury [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/7\">",
"       7",
"      </a>",
"      ]. Thus, the beneficial effects of aggressive antiplatelet therapies, including glycoprotein IIbIIIa inhibitors, may be due in part to prevention of microvascular dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/41-44\">",
"       41-44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Platelet activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complement activation (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Complement activation'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Myocardial stunning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myocardial stunning refers to transient, myocardial dysfunction that occurs after reperfusion, as opposed to dysfunctional hibernating myocardium secondary to ongoing ischemia. It is thought to result from persistent anaerobic metabolism that continues after reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/20\">",
"     20",
"    </a>",
"    ]. Myocardial stunning is also associated with microvascular injury and better levels of regional and global myocardial function are seen when the microvasculature is structurally intact [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/39,45-47\">",
"     39,45-47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because stunning can recover with time, inotropic agents can be used in the short-term to improve cardiac function and organ perfusion. Several agents that may prevent its occurrence are being investigated. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Potential therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Myocyte death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most concerning consequence of reperfusion injury is myocyte death. Animal data suggest that up to 50 percent of an infarct size may be attributable to reperfusion injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. This observation highlights the potential value of therapies that reduce or eliminate reperfusion injury. Despite an improved understanding of the processes associated with reperfusion injury, there is still uncertainty regarding the magnitude and significance of myocyte death associated with reperfusion.",
"   </p>",
"   <p>",
"    If a substantial percentage of myocardial injury during an acute MI occurs after reperfusion, a central question is whether reperfusion hastens the development of injury already incurred during the preceding ischemic period, or does reperfusion cause additional damage beyond that accounted for by the ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/50\">",
"     50",
"    </a>",
"    ]. Because it is technically impossible to follow the progression of injury in the myocardium before and after reperfusion, studies have focused on modifying the conditions of reperfusion to see if there is any effect on the extent of end-damage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     POTENTIAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathophysiology of reperfusion injury lends itself to potential therapeutic strategies, few treatments have found their way into clinical practice.",
"   </p>",
"   <p>",
"    Potential reasons for the ultimate failure of agents that appeared promising in preclinical trials include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple mechanisms contribute to the consequences of myocardial infarction and reperfusion injury. Thus, the impact of a therapy targeted to single component of the pathophysiology may be diluted in clinical practice.",
"     </li>",
"     <li>",
"      Some mechanisms, such as neutrophil stimulation, may be mediators of injury, but also play important roles in the healing process [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/23\">",
"       23",
"      </a>",
"      ]. Targeting such mechanisms would have complex and unpredictable implications on outcomes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Leukocyte aggregation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It may not be possible to administer a therapy at the optimal time in clinical practice (eg, some agents may perform best if patients are pretreated).",
"     </li>",
"     <li>",
"      The presence of comorbidities, such as diabetes and hypercholesterolemia, may impact the efficacy of a new treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identification of patients at highest risk of reperfusion injury may be an important component of bringing therapies into clinical practice. As an example, myocardial blush grade has been used as a tool to evaluate myocardial level perfusion, and low blush grades correlate with myocardial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Such tools may also allow for better clinical assessment of therapeutic effectiveness of drugs tested in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI myocardial perfusion grade'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Glycoprotein IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet activation contributes to microvascular injury and reperfusion injury in acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Platelet activation'",
"    </a>",
"    above.) Glycoprotein IIbIIIa inhibitors are potent inhibitors of platelet activity that improve outcomes in acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/41-44\">",
"     41-44",
"    </a>",
"    ]. It is not known if part of the benefit of glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIa",
"    </span>",
"    inhibitors is due to a reduction in reperfusion injury. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H4#H4\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'No-reflow phenomenon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine has several properties that make it an attractive candidate to prevent reperfusion injury. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is a substrate for ATP replenishment",
"     </li>",
"     <li>",
"      Vasodilation",
"     </li>",
"     <li>",
"      Platelet and neutrophil inhibition",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these properties, adenosine has been tested in both preclinical and clinical studies. The demonstration of cardioprotective effects of adenosine in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/55-57\">",
"     55-57",
"    </a>",
"    ] provided the rationale for randomized clinical trials. The following are representative studies that have shown mixed results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the AMISTAD trial, 236 patients with an acute MI treated with fibrinolysis were randomly assigned to adenosine or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/58\">",
"       58",
"      </a>",
"      ]. At a follow-up of six days, infarction size was significantly smaller in patients assigned to adenosine treatment, a benefit that was limited to those with anterior infarctions.",
"     </li>",
"     <li>",
"      AMISTAD 2 is the largest trial of intravenous adenosine as an adjunctive therapy during primary reperfusion for an acute MI [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. This study included 2118 patients treated with primary PCI or fibrinolytic therapy for anterior ST elevation MI. Although infarct size was reduced with adenosine, there was no reduction in a combined clinical end point of heart failure or overall mortality at six months.",
"     </li>",
"     <li>",
"      In the PREVENT-ICARUS trial, 260 patients undergoing elective PCI were randomly assigned to either intracoronary adenosine or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/61\">",
"       61",
"      </a>",
"      ]. There was no significant difference between the two groups in the primary end point of a periprocedural increase in troponin I &gt; three times the upper limit of normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the administration of either intravenous or intracoronary adenosine has not been established as an effective therapy to reduce the risk of clinical events after PCI in either stable patients or those with acute coronary syndromes. Adequately powered studies to evaluate whether intracoronary adenosine leads to improved clinical outcomes are unlikely to be performed",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of vasodilators have been investigated as potential therapies for reperfusion injury.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human studies with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/2/37923?source=see_link\">",
"       papaverine",
"      </a>",
"      have also demonstrated success in improving angiographically documented TIMI flow grades in epicardial arteries, however its use is limited by occurrence of ventricular arrhythmias, especially with intracoronary administration [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several members of the sydnonimine class of NO donors have reduced infarct size in an animal model [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/63,64\">",
"       63,64",
"      </a>",
"      ]. These compounds spontaneously decompose to form NO.",
"     </li>",
"     <li>",
"      ACE inhibitors may have several beneficial actions in reperfusion, including the scavenging of free radicals, vasodilation of the coronary bed, and elevation of prostacyclin and bradykinin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/65\">",
"       65",
"      </a>",
"      ]. In an animal model, ACE inhibitors enhanced coronary blood flow, but failed to produce any improvement in regional ventricular function [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endothelin is a potent vasoconstrictor and possible mediator of the vasospastic component of reperfusion injury. Several studies have investigated the effects of inhibiting endothelin-1 synthesis or blocking its receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/67-70\">",
"       67-70",
"      </a>",
"      ]. Although conflicting results have been reported, further study is ongoing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ion channel modulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in intracellular and extracellular ion concentrations and pH play a role in some of the processes involved in reperfusion injury. Thus, ion channels are an attractive target for novel treatments of reperfusion injury. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mitochondrial dysfunction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H5\">",
"     'Myocyte hypercontracture'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The potential role of ion channel modulation in the treatment of reperfusion injury is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Na/H",
"      </span>",
"      exchange inhibition &mdash;",
"      <span class=\"nowrap\">",
"       Sodium/hydrogen",
"      </span>",
"      exchange is an important regulator of intracellular pH and calcium concentration. Blockade of this exchange reduces calcium uptake and helps to preserve cellular architecture [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/71\">",
"       71",
"      </a>",
"      ]. Several in vitro and animal studies have suggested that inhibition of",
"      <span class=\"nowrap\">",
"       sodium/hydrogen",
"      </span>",
"      exchange is effective in reducing reperfusion injury and infarct size [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/71-74\">",
"       71-74",
"      </a>",
"      ]. However, in a two-stage randomized trial including a total of 1389 patients, the",
"      <span class=\"nowrap\">",
"       sodium/hydrogen",
"      </span>",
"      exchange inhibitor eniporide did not improve infarct size or clinical outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/2/34854?source=see_link\">",
"       Ranolazine",
"      </a>",
"      &mdash; Ranolazine is effective in the treatment of chronic angina, and may be effective in reperfusion injury and limit infarct size in acute myocardial infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/77\">",
"       77",
"      </a>",
"      ]. Ranolazine is an inhibitor of the late sodium channel, and via this mechanism decreases sodium dependent intracellular calcium overload during ischemia and reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=see_link&amp;anchor=H3#H3\">",
"       \"New therapies for angina pectoris\", section on 'Ranolazine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      K-ATP-channel openers &mdash; Potassium-ATP (K-ATP) channels are involved in ischemic preconditioning and microvascular vasodilation. In small clinical trials, K-ATP channel openers such as nicorandil, resulted in better perfusion and left ventricular wall motion, as well as a reduction in adverse events [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. Cardiac magnetic resonance imaging data suggest that nicorandil may improve microvascular obstruction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     GIK solution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-insulin-potassium (GIK) therapy has been tested as a potential way to stimulate anaerobic glycolysis, increase ATP levels, and decrease the free fatty acid release. Although initial trials suggested a benefit with this therapy, larger trials including CREATE-ECLA and DIGAMI 2 showed no benefit with GIK.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Antineutrophil and anticomplement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibition of the accumulation and activation of neutrophils has been correlated with a reduced infarct size in some studies, although other trials have failed to show a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/52,83-85\">",
"     52,83-85",
"    </a>",
"    ]. Unfortunately, the prolonged time from the onset of infarction to the delivery of antineutrophil therapy such as CD18 may reduce the ability of these agents to mitigate neutrophil-mediated cell injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly disappointing were results reported for the complement inhibitor pexelizumab [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/86-88\">",
"     86-88",
"    </a>",
"    ]. This may be due to the complexity and the multiple steps of immune activation involved in reperfusion injury. Part of the success of the intracoronary glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor administration in PCI may be also due to its effect on leukocyte integrin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Glycoprotein IIb/IIIa inhibitors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Antioxidant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prominent role of oxygen radicals in the pathophysiology of reperfusion injury has prompted several studies to evaluate the efficacy of antioxidants in reducing the damage associated with reperfusion. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Oxygen and other free radicals'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The results have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/90\">",
"     90",
"    </a>",
"    ] and investigation remains focused at the animal level. Erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/25,91-94\">",
"     25,91-94",
"    </a>",
"    ], estrogen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/95,96\">",
"     95,96",
"    </a>",
"    ], heme oxygenase1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/97\">",
"     97",
"    </a>",
"    ], and hypoxia induced factor&ndash;1 (HIF-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/98\">",
"     98",
"    </a>",
"    ] have all been shown to reduce reperfusion injury, and investigation is ongoing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Magnesium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of magnesium in minimizing reperfusion injury was first evaluated in a large placebo controlled trial in the Fourth International Study of Infarct Survival (ISIS-4) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/99\">",
"     99",
"    </a>",
"    ]. Magnesium infusions were administered for 24 hours to patients presenting with suspected acute myocardial infarction, but failed to show any benefit. However, controversy over the role of magnesium has persisted because the infusion was not started until after the time of reperfusion. The subsequent MAGIC trial showed that magnesium infusion has no effect on mortality even when administered at the time of reperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/469?source=see_link\">",
"     \"Intravenous magnesium sulfate in acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to its well know immunosuppressive effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    can limit reperfusion injury by potently inhibiting opening of the mitochondrial permeability-transition pore [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/101\">",
"     101",
"    </a>",
"    ]. A pilot study of 58 patients showed that a single intravenous bolus of cyclosporine administered before primary PCI results in a reduction of Creatinine kinase by 44 percent and in a subset of 27 patients, this translated into a 20 percent reduction in infarct size as measured by delayed enhancement cardiac MR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Ischemic postconditioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic postconditioning refers to the ability of a series of brief coronary artery occlusions after a severe ischemic insult to protect against ischemic-reperfusion injury of the myocardium. In animal models, ischemic postconditioning is almost as effective as ischemic preconditioning and involves similar pathogenetic mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and pathogenesis of ischemic preconditioning\", section on 'Ischemic preconditioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It appears to affect cardioprotection by activating survival protein kinases of the reperfusion-injury salvage kinase pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. Postconditioning reduces the number of necrotic, apoptotic, and autophagic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When applied to patients with ST-segment elevation myocardial infarction, this interventional technique involves repeated short balloon inflations at low pressure to temporarily occlude the infarct-related artery after patency has been achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Forearm studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial insights into the potential timing of ischemic postconditioning in humans were provided by a forearm model of ischemic postconditioning [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/108\">",
"     108",
"    </a>",
"    ]. After 20 minutes of sustained forearm ischemia, and at the onset of 20 minutes of reperfusion, an ischemic postconditioning protocol was applied comprising three 10 or 30 second cycles of alternate ischemia and reperfusion. The following findings were observed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic postconditioning improved endothelial function.",
"     </li>",
"     <li>",
"      Both 10 and 30 second postconditioning protocols were comparably effective.",
"     </li>",
"     <li>",
"      No protection was observed if application of the postconditioning protocol was delayed for one minute, a finding that supports preclinical studies in which the postconditioning protocol needs to be instituted within one minute of full reflow [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/109\">",
"       109",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Primary PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of ischemic postconditioning in humans has been illustrated in three randomized, pilot trials of (17, 30 and 38) patients who received successful primary PCI for ST-segment elevation myocardial infarction. Patients who received ischemic post conditioning, as opposed to usual care, were seen to derive the following benefits in these studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Greater attenuation of ST-segment elevation and improved distal coronary artery flow [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significant reduction of 36 percent compared to the control group in infarct size, as estimated from total creatine kinase release over 72 hours and a significantly increased (2.44 versus 1.95) myocardial blush grade, a marker of myocardial reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/111\">",
"       111",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H19#H19\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'Infarct size'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=see_link&amp;anchor=H6#H6\">",
"       \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI myocardial perfusion grade'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A reduction in infarct size on SPECT imaging at six months and a 7 percent improvement in ejection fraction at one year in patients assigned to ischemic postconditioning after stenting [",
"      <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations should be considered preliminary. Before postconditioning can be recommended in patients who undergo primary PCI, additional studies are needed to confirm efficacy in a larger number of patients, to determine the optimal protocol, to assess treatment effect using a more accepted measure of infarct size after reperfusion (eg, SPECT imaging), and to determine long-term outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic postconditioning has potential clinical applications since it might be performed at the time of reperfusion by percutaneous coronary intervention for acute myocardial infarction or at the time of coronary artery bypass graft surgery.",
"   </p>",
"   <p>",
"    Another mechanical solution that has shown some effectiveness in animal models, in surgical patients and patients treated with thrombolysis is a Percutaneous Intermittent Coronary Sinus Occlusion device that may work by improving collateral recruitment, increased NO production and wash-out of oxidative radicals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Endovascular cooling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The premise of endovascular cooling is that myocardial metabolism will be decreased at lower temperatures and thus some cardioprotection will be afforded, analogous to cold cardioplegia used by cardiac surgeons during coronary bypass grafting. Endovascular coils and external cooling blankets are used to bring the core temperature of a patient down to 33 degrees Celsius during PCI for acute myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?6/15/6394/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. COOL MI, a trial in 356 patients undergoing primary PCI, showed reduction in infarct size in the subgroup of patients with an anterior MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic reperfusion injury is an important limitation to the efficacy of primary reperfusion therapies in acute MI. Clinical manifestations include arrhythmias, microvascular dysfunction, and myocyte dysfunction and death. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The etiology of reperfusion injury is complex, involving abnormalities in energy production and utilization, disturbance of cellular architecture, and possibly leukocyte, platelet, and complement activation. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Pathophysiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Therapies specifically targeted to the prevention reperfusion injury are not available for clinical use. Despite ongoing improvements in the understanding of the underlying mechanisms and a wide range of potential treatments under investigation, effective therapies remain elusive. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Potential therapies'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/1\">",
"      Simoons ML, Serruys PW, van den Brand M, et al. Early thrombolysis in acute myocardial infarction: limitation of infarct size and improved survival. J Am Coll Cardiol 1986; 7:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/2\">",
"      White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/3\">",
"      Sheehan FH, Doerr R, Schmidt WG, et al. Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: an important determinant of survival. J Am Coll Cardiol 1988; 12:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/4\">",
"      Bolli R, Becker L, Gross G, et al. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004; 95:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/5\">",
"      Cannon RO 3rd. Mechanisms, management and future directions for reperfusion injury after acute myocardial infarction. Nat Clin Pract Cardiovasc Med 2005; 2:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/6\">",
"      Jennings RB, Murry CE, Steenbergen C Jr, Reimer KA. Development of cell injury in sustained acute ischemia. Circulation 1990; 82:II2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/7\">",
"      Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2006; 290:H692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/8\">",
"      Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation 2002; 105:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/9\">",
"      Bialik S, Cryns VL, Drincic A, et al. The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes. Circ Res 1999; 85:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/10\">",
"      Saraste A, Pulkki K, Kallajoki M, et al. Apoptosis in human acute myocardial infarction. Circulation 1997; 95:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/11\">",
"      Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion--a target for cardioprotection. Cardiovasc Res 2004; 61:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/12\">",
"      Zhou HZ, Swanson RA, Simonis U, et al. Poly(ADP-ribose) polymerase-1 hyperactivation and impairment of mitochondrial respiratory chain complex I function in reperfused mouse hearts. Am J Physiol Heart Circ Physiol 2006; 291:H714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/13\">",
"      Zingarelli B, Hake PW, O'Connor M, et al. Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury. Mol Med 2003; 9:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/14\">",
"      Zingarelli B, O'Connor M, Hake PW. Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis. Eur J Pharmacol 2003; 469:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/15\">",
"      Ladilov YV, Siegmund B, Balser C, Piper HM. Simulated ischemia increases the susceptibility of rat cardiomyocytes to hypercontracture. Circ Res 1997; 80:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/16\">",
"      Meissner A, Morgan JP. Contractile dysfunction and abnormal Ca2+ modulation during postischemic reperfusion in rat heart. Am J Physiol 1995; 268:H100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/17\">",
"      Ladilov YV, Siegmund B, Piper HM. Protection of reoxygenated cardiomyocytes against hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol 1995; 268:H1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/18\">",
"      Piper HM, Garc&iacute;a-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998; 38:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/19\">",
"      Bolli R, Jeroudi MO, Patel BS, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci U S A 1989; 86:4695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/20\">",
"      Verma S, Fedak PW, Weisel RD, et al. Fundamentals of reperfusion injury for the clinical cardiologist. Circulation 2002; 105:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/21\">",
"      Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathol Int 1999; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/22\">",
"      Salvemini D, Cuzzocrea S. Superoxide, superoxide dismutase and ischemic injury. Curr Opin Investig Drugs 2002; 3:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/23\">",
"      Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/24\">",
"      Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res 2006; 98:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/25\">",
"      Namiuchi S, Kagaya Y, Ohta J, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/26\">",
"      Becker LC. Myocardial Reperfusion Injury. J Thromb Thrombolysis 1997; 4:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/27\">",
"      Engler RL, Schmid-Sch&ouml;nbein GW, Pavelec RS. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 1983; 111:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/28\">",
"      Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. J Pathol 2000; 190:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/29\">",
"      Pan&eacute;s J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999; 126:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/30\">",
"      Umansky SR, Cuenco GM, Khutzian SS, et al. Post-ischemic apoptotic death of rat neonatal cardiomyocytes. Cell Death Differ 1995; 2:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/31\">",
"      Gottlieb RA, Burleson KO, Kloner RA, et al. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/32\">",
"      Piot CA, Wolfe CL. Apoptosis: A New Mechanism of Lethal Myocardial \"Reperfusion Injury\"? J Thromb Thrombolysis 1997; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/33\">",
"      Zhao ZQ, Velez DA, Wang NP, et al. Progressively developed myocardial apoptotic cell death during late phase of reperfusion. Apoptosis 2001; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/34\">",
"      Zhao ZQ, Vinten-Johansen J. Myocardial apoptosis and ischemic preconditioning. Cardiovasc Res 2002; 55:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/35\">",
"      Zhang YQ, Herman B. ARC protects rat cardiomyocytes against oxidative stress through inhibition of caspase-2 mediated mitochondrial pathway. J Cell Biochem 2006; 99:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/36\">",
"      Donath S, Li P, Willenbockel C, et al. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation 2006; 113:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/37\">",
"      Akar FG, Aon MA, Tomaselli GF, O'Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest 2005; 115:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/38\">",
"      Berger PB, Ruocco NA, Ryan TJ, et al. Incidence and significance of ventricular tachycardia and fibrillation in the absence of hypotension or heart failure in acute myocardial infarction treated with recombinant tissue-type plasminogen activator: results from the Thrombolysis in Myocardial Infarction (TIMI) Phase II trial. J Am Coll Cardiol 1993; 22:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/39\">",
"      Iliceto S, Galiuto L, Marchese A, et al. Analysis of microvascular integrity, contractile reserve, and myocardial viability after acute myocardial infarction by dobutamine echocardiography and myocardial contrast echocardiography. Am J Cardiol 1996; 77:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/40\">",
"      Hoffmann R, Haager P, Lepper W, et al. Relation of coronary flow pattern to myocardial blush grade in patients with first acute myocardial infarction. Heart 2003; 89:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/41\">",
"      Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/42\">",
"      Neumann FJ, Blasini R, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998; 98:2695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/43\">",
"      de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation 2000; 101:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/44\">",
"      Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 2003; 42:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/45\">",
"      Iliceto S, Galiuto L, Marchese A, et al. Functional role of microvascular integrity in patients with infarct-related artery patency after acute myocardial infarction. Eur Heart J 1997; 18:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/46\">",
"      Ito H, Maruyama A, Iwakura K, et al. Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996; 93:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/47\">",
"      Sabia PJ, Powers ER, Ragosta M, et al. An association between collateral blood flow and myocardial viability in patients with recent myocardial infarction. N Engl J Med 1992; 327:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/48\">",
"      Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998; 97:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/49\">",
"      Arai M, Lefer DJ, So T, et al. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion. J Am Coll Cardiol 1996; 27:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/50\">",
"      Hearse DJ. Ischemia, reperfusion, and the determinants of tissue injury. Cardiovasc Drugs Ther 1990; 4 Suppl 4:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/51\">",
"      Ferrari R, Hearse DJ. Reperfusion Injury: Does It Exist and Does It Have Clinical Relevance? J Thromb Thrombolysis 1997; 4:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/52\">",
"      Baran KW, Nguyen M, McKendall GR, et al. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study. Circulation 2001; 104:2778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/53\">",
"      Hoffmann R, Haager P, Arning J, et al. Usefulness of myocardial blush grade early and late after primary coronary angioplasty for acute myocardial infarction in predicting left ventricular function. Am J Cardiol 2003; 92:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/54\">",
"      Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/55\">",
"      Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation 1992; 85:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/56\">",
"      Headrick JP, Hack B, Ashton KJ. Acute adenosinergic cardioprotection in ischemic-reperfused hearts. Am J Physiol Heart Circ Physiol 2003; 285:H1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/57\">",
"      Morrison RR, Teng B, Oldenburg PJ, et al. Effects of targeted deletion of A1 adenosine receptors on postischemic cardiac function and expression of adenosine receptor subtypes. Am J Physiol Heart Circ Physiol 2006; 291:H1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/58\">",
"      Mahaffey KW, Puma JA, Barbagelata NA, et al. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol 1999; 34:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/59\">",
"      Ross AM, Gibbons RJ, Stone GW, et al. A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005; 45:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/60\">",
"      Kloner RA, Forman MB, Gibbons RJ, et al. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J 2006; 27:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/61\">",
"      De Luca G, Iorio S, Venegoni L, Marino P. Evaluation of intracoronary adenosine to prevent periprocedural myonecrosis in elective percutaneous coronary intervention (from the PREVENT-ICARUS Trial). Am J Cardiol 2012; 109:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/62\">",
"      Ishihara M, Sato H, Tateishi H, et al. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine. Am Heart J 1996; 132:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/63\">",
"      Siegfried MR, Erhardt J, Rider T, et al. Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion. J Pharmacol Exp Ther 1992; 260:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/64\">",
"      Schl&uuml;ter KD, Weber M, Schraven E, Piper HM. NO donor SIN-1 protects against reoxygenation-induced cardiomyocyte injury by a dual action. Am J Physiol 1994; 267:H1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/65\">",
"      Van Gilst, WH, Kingma, JH. Protection of the myocardium against postischemic reperfusion damage: possible role of angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1992; 19:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/66\">",
"      Piana RN, Wang SY, Friedman M, Sellke FW. Angiotensin-converting enzyme inhibition preserves endothelium-dependent coronary microvascular responses during short-term ischemia-reperfusion. Circulation 1996; 93:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/67\">",
"      Wang QD, Li XS, Lundberg JM, Pernow J. Protective effects of non-peptide endothelin receptor antagonist bosentan on myocardial ischaemic and reperfusion injury in the pig. Cardiovasc Res 1995; 29:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/68\">",
"      Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993; 27:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/69\">",
"      Pernow J, Wang QD. Endothelin in myocardial ischaemia and reperfusion. Cardiovasc Res 1997; 33:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/70\">",
"      Galiuto, L, DeMaria, AN, del Balzo, U, et al. Endothelin A-antagonist reduces no-reflow and infarct size in dogs. J Am Coll Cardiol 1999; Special Issue (Suppl): 382A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/71\">",
"      Klein HH, Pich S, Bohle RM, et al. Myocardial protection by Na(+)-H+ exchange inhibition in ischemic, reperfused porcine hearts. Circulation 1995; 92:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/72\">",
"      Meng HP, Maddaford TG, Pierce GN. Effect of amiloride and selected analogues on postischemic recovery of cardiac contractile function. Am J Physiol 1993; 264:H1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/73\">",
"      Hendrikx M, Mubagwa K, Verdonck F, et al. New Na(+)-H+ exchange inhibitor HOE 694 improves postischemic function and high-energy phosphate resynthesis and reduces Ca2+ overload in isolated perfused rabbit heart. Circulation 1994; 89:2787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/74\">",
"      Rohmann S, Weygandt H, Minck KO. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res 1995; 30:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/75\">",
"      Coletta AP, Cleland JG. Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology--WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 2001; 3:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/76\">",
"      Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001; 38:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/77\">",
"      Hale SL, Leeka JA, Kloner RA. Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J Pharmacol Exp Ther 2006; 318:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/78\">",
"      Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/79\">",
"      Belardinelli L, Shryock JC, Fraser H. Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart 2006; 92 Suppl 4:iv6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/80\">",
"      Sakata Y, Kodama K, Ishikura F, et al. Disappearance of the 'no-reflow' phenomenon after adjunctive intracoronary administration of nicorandil in a patient with acute myocardial infarction. Jpn Circ J 1997; 61:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/81\">",
"      Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999; 33:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/82\">",
"      Krombach GA, Higgins CB, Chujo M, Saeed M. Gadomer-enhanced MR imaging in the detection of microvascular obstruction: alleviation with nicorandil therapy. Radiology 2005; 236:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/83\">",
"      Gonon AT, Gourine AV, Middelveld RJ, et al. Limitation of infarct size and attenuation of myeloperoxidase activity by an endothelin A receptor antagonist following ischaemia and reperfusion. Basic Res Cardiol 2001; 96:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/84\">",
"      Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30:S214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/85\">",
"      Faxon DP, Gibbons RJ, Chronos NA, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol 2002; 40:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/86\">",
"      Mahaffey KW, Granger CB, Nicolau JC, et al. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/87\">",
"      Granger CB, Mahaffey KW, Weaver WD, et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/88\">",
"      APEX AMI Investigators, Armstrong PW, Granger CB, et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/89\">",
"      Simon DI, Xu H, Ortlepp S, et al. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/90\">",
"      Przyklenk K. Pharmacologic treatment of the stunned myocardium: the concepts and the challenges. Coron Artery Dis 2001; 12:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/91\">",
"      Hanlon PR, Fu P, Wright GL, et al. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J 2005; 19:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/92\">",
"      Bullard AJ, Govewalla P, Yellon DM. Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 2005; 100:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/93\">",
"      Xu B, Dong GH, Liu H, et al. Recombinant human erythropoietin pretreatment attenuates myocardial infarct size: a possible mechanism involves heat shock Protein 70 and attenuation of nuclear factor-kappaB. Ann Clin Lab Sci 2005; 35:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/94\">",
"      Hirata A, Minamino T, Asanuma H, et al. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Cardiovasc Drugs Ther 2005; 19:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/95\">",
"      Jeanes HL, Wanikiat P, Sharif I, Gray GA. Medroxyprogesterone acetate inhibits the cardioprotective effect of estrogen in experimental ischemia-reperfusion injury. Menopause 2006; 13:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/96\">",
"      Sbarouni E, Iliodromitis EK, Bofilis E, et al. Estrogen alone or combined with medroxyprogesterone but not raloxifene reduce myocardial infarct size. Eur J Pharmacol 2003; 467:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/97\">",
"      Liu X, Pachori AS, Ward CA, et al. Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J 2006; 20:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/98\">",
"      Jung F, Palmer LA, Zhou N, Johns RA. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ Res 2000; 86:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/99\">",
"      ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/100\">",
"      Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/101\">",
"      Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003; 60:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/102\">",
"      Piot C, Croisille P, Staat P, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008; 359:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/103\">",
"      Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003; 285:H579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/104\">",
"      Argaud L, Gateau-Roesch O, Raisky O, et al. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005; 111:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/105\">",
"      Yang XM, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004; 44:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/106\">",
"      Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of \"modified reperfusion\" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004; 95:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/107\">",
"      Zhao ZQ, Vinten-Johansen J. Postconditioning: reduction of reperfusion-induced injury. Cardiovasc Res 2006; 70:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/108\">",
"      Loukogeorgakis SP, Panagiotidou AT, Yellon DM, et al. Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation 2006; 113:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/109\">",
"      Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. Am J Physiol Heart Circ Physiol 2005; 289:H2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/110\">",
"      Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter Cardiovasc Interv 2005; 65:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/111\">",
"      Staat P, Rioufol G, Piot C, et al. Postconditioning the human heart. Circulation 2005; 112:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/112\">",
"      Thibault H, Piot C, Staat P, et al. Long-term benefit of postconditioning. Circulation 2008; 117:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/113\">",
"      Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005; 112:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/114\">",
"      Mohl W, Komamura K, Kasahara H, et al. Myocardial protection via the coronary sinus. Circ J 2008; 72:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/115\">",
"      Dixon SR, Whitbourn RJ, Dae MW, et al. Induction of mild systemic hypothermia with endovascular cooling during primary percutaneous coronary intervention for acute myocardial infarction. J Am Coll Cardiol 2002; 40:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/116\">",
"      Ly HQ, Denault A, Dupuis J, et al. A pilot study: the Noninvasive Surface Cooling Thermoregulatory System for Mild Hypothermia Induction in Acute Myocardial Infarction (the NICAMI Study). Am Heart J 2005; 150:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/15/6394/abstract/117\">",
"      Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study). Am J Cardiol 2004; 93:636.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1511 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6394=[""].join("\n");
var outline_f6_15_6394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitochondrial dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Myocyte hypercontracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxygen and other free radicals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Leukocyte aggregation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Platelet activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Apoptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Microvascular dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Myocardial stunning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Myocyte death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      POTENTIAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Glycoprotein IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adenosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ion channel modulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      GIK solution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Antineutrophil and anticomplement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Antioxidant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Magnesium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Ischemic postconditioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Forearm studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Primary PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Endovascular cooling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9673?source=related_link\">",
"      Definition and pathogenesis of ischemic preconditioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/469?source=related_link\">",
"      Intravenous magnesium sulfate in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/37/39513?source=related_link\">",
"      New therapies for angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/17/12570?source=related_link\">",
"      Pathogenesis of ventricular tachycardia and ventricular fibrillation during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_15_6395="Age of suture closure";
var content_f6_15_6395=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Age of suture closure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Suture",
"       </td>",
"       <td class=\"subtitle1\">",
"        Begins closure, months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metopic",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sagittal",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronal",
"       </td>",
"       <td>",
"        24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambdoid",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palatal",
"       </td>",
"       <td>",
"        30 to 35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frontonasal",
"       </td>",
"       <td>",
"        68",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Frontozygomatic",
"       </td>",
"       <td>",
"        72",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6395=[""].join("\n");
var outline_f6_15_6395=null;
var title_f6_15_6396="Asbestosis and job risk";
var content_f6_15_6396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67902&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Occupations and industries associated with asbestosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Occupations",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plumbers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pipefitters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Steamfitters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Electricians",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulation workers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carpenters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Laborers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Boilermakers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Welders and cutters",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Janitors",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Industries",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Construction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Shipbuilding and repairing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chemicals and other manufacturing",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nonmetallic mineral stone products",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Railways",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Yarn, thread, and fabric mills",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trucking",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plastic and rubber manufacture",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Wagner, GR, Lancet 1997; 349:1311.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6396=[""].join("\n");
var outline_f6_15_6396=null;
var title_f6_15_6397="Common causes of out-toeing";
var content_f6_15_6397=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80335&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of common causes of out-toeing in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        External rotation contracture of the hip",
"       </td>",
"       <td class=\"subtitle1\">",
"        External tibial torsion",
"       </td>",
"       <td class=\"subtitle1\">",
"        Femoral retroversion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Description",
"        </strong>",
"       </td>",
"       <td>",
"        Physiologic contracture related to intrauterine positioning",
"       </td>",
"       <td>",
"        External (lateral) rotation of the tibia relative to the transcondylar axis of the femur",
"       </td>",
"       <td>",
"        Decreased angle of rotation between the axis of the femoral neck and the transcondylar axis of the femur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Most common age group",
"        </strong>",
"       </td>",
"       <td>",
"        Birth to one year",
"       </td>",
"       <td>",
"        Late childhood, early adolescence",
"       </td>",
"       <td>",
"        Older than three years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Foot progression angle",
"        </strong>",
"       </td>",
"       <td>",
"        External",
"       </td>",
"       <td>",
"        External",
"       </td>",
"       <td>",
"        External",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patellar progression angle",
"        </strong>",
"       </td>",
"       <td>",
"        External",
"       </td>",
"       <td>",
"        Neutral or external",
"       </td>",
"       <td>",
"        External",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Evaluation",
"        </strong>",
"       </td>",
"       <td>",
"        Increased external hip rotation; decreased internal hip rotation*",
"       </td>",
"       <td>",
"        Thigh foot angle",
"        <sup>",
"         &bull;",
"        </sup>",
"        is external (positive)",
"       </td>",
"       <td>",
"        Increased external hip rotation; decreased internal hip rotation*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Laterality",
"        </strong>",
"       </td>",
"       <td>",
"        Usually bilateral and symmetrical",
"       </td>",
"       <td>",
"        Often unilateral with the right side more often affected",
"       </td>",
"       <td>",
"        Usually bilateral and symmetrical; when unilateral the right side is more often affected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Other clinical features",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Medial malleolus anterior to lateral malleolus when seated with thigh directly in front of hip joint and the knee pointed straight ahead",
"        </p>",
"        <p>",
"         May be associated with knock-knees",
"        </p>",
"        <p>",
"         May be associated with prematurity and prone positioning",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Rare",
"        </p>",
"        <p>",
"         More commonly seen in obese children",
"        </p>",
"        <p>",
"         May be associated with slipped capital femoral epiphysis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Natural history",
"        </strong>",
"       </td>",
"       <td>",
"        Usually resolves by 12 months",
"       </td>",
"       <td>",
"        Usually does not correct spontaneously; may worsen over time, but rarely causes problems or sequelae (eg, patellofemoral pain or instability, arthritis of the knee)",
"       </td>",
"       <td>",
"        <p>",
"         Does not improve spontaneously",
"        </p>",
"        <p>",
"         May be associated with hip or knee arthritis, stress fractures, and slipped capital femoral epiphysis",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Hip rotation is measured with the child prone and the knees flexed. To assess external hip rotation, the lower leg is rotated toward the axis of the body; to assess internal rotation, the lower leg is rotated away from the axis of the body. (See text for details).",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      The thigh-foot angle is measured with the child prone, the knee flexed, and the ankle dorsiflexed so that the plantar surface of the foot is parallel to the ceiling. A visual line is approximated along the long axis of the thigh and a second line along the long axis of the heel. The angle between these two lines is the thigh-foot angle. (See text for details).",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6397=[""].join("\n");
var outline_f6_15_6397=null;
var title_f6_15_6398="Extraction ratios";
var content_f6_15_6398=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52578&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The relationship between oxygen consumption (VO2), oxygen delivery (DO2), and the extraction ratio",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 428px; height: 570px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) An inverse relationship exists between oxygen delivery (DO",
"    <sub>",
"     2",
"    </sub>",
"    ) and the extraction raio (ER), with no correlation between oxygen consumption (VO",
"    <sub>",
"     2",
"    </sub>",
"    ) and the ER.",
"    <br/>",
"    (B) An improved ability to extract oxygen during exercise exists at all levels of DO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6398=[""].join("\n");
var outline_f6_15_6398=null;
var title_f6_15_6399="C1 complement complex";
var content_f6_15_6399=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F63027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F63027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of the complement component 1 (C1) complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 255px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A model of the C1 complex showing the intertwining of C1s-C1r-C1r-C1s in the C1q subcomponent. This structure permits the catalytic domains of C1s to contact the catalytic domains of C1r. The Fc portion of IgG and IgM engages the globular head of C1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Liszewski, MK, Atkinson, JP. The complement system. In: Immunology Scope Monograph, Schwart BD (Ed), Upjohn, Kalamazoo 1992.) Structure of C1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_15_6399=[""].join("\n");
var outline_f6_15_6399=null;
